2000
- Four-Wheel Drive Vehicles Needed to Deliver Critical Meals to People Living with HIV/AIDS and Other Life-Threatening Illnesses: Food & Friends Can't Close During Bad Weather
- PRNewswire - December 29, 2000
- WASHINGTON, Dec. 29 /PRNewswire/ -- Food & Friends, an organization that delivers critical nutritious meals to people living with HIV/AIDS and other life-threatening illnesses throughout the Washington Metropolitan area, is planning ahead to have enough volunteers during upcoming winter storms. Food & Friends m
- Demegen Reports Favorable Results For Microbicide
- PRNewswire - Thursday December 21, 2000
- PITTSBURGH, Dec. 21 /PRNewswire/ -- Demegen, Inc. (OTC Bulletin Board: DBOT - news) reports confirmation that Demegen s antimicrobial peptide vaginal microbicide is effective in killing Chlamydia, a sexually transmitted organism that infects over 4 million people annually in the USA. These new research results are impo
- Regulatory Approval Granted in France for Visible Genetics TRUGENE HIV-1 Genotyping Kit
- PRNewswire - Wednesday December 20, 2000
- TORONTO, Dec. 20 /PRNewswire/ -- Visible Genetics Inc. (VGI) (Nasdaq: VGIN - news) reported today that it has been granted French regulatory approval for its TRUGENE(TM) HIV-1 Genotyping Kit by the Agence Francaise De Securite Sanitaire Des Produits de Sante (AFSSAPS). Visible Genetics TRUGENE HIV-1 Genotyping Kit is t
- The Chicken Soup Brigade Receives $4,000 in Donated Furnishings
- PRNewswire - Tuesday December 19, 2000
- SEATTLE, Dec. 19 /PRNewswire/ -- The Chicken Soup Brigade, which provides support services to people with HIV and AIDS, today will receive the gift of $4,000 worth of gently used home furnishings for its Thrift Store through an annual holiday donation program, Sharing With Our Communities, coordinated by ExecuStay by M
- PTC Therapeutics Awarded Phase I SBIR Grant to Develop Novel HIV Treatments
- PRNewswire - Tuesday December 19, 2000
- SOUTH PLAINFIELD, N.J., Dec. 19 /PRNewswire/ -- PTC Therapeutics today announced the Company has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Institutes of Health. Funding from this grant will be used to advance PTC s RNA-based approach for developing novel HIV drugs that tar
- Hollis-Eden Announces Presentation of Additional HE2000 HIV Clinical Data: New Findings Include Improvements in Key Dendritic Cells And Increased Hematopoesis
- PRNewswire - December 18, 2000
- SAN JUAN, Puerto Rico , Dec. 18 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced presentations of HE2000 clinical data at the Frontiers in Drug Development for Antiretroviral Therapies (HIV DART) meeting being held in San Juan, Puerto Rico December 17-21. HE2000 is the subject of an ora
- Hollis-Eden Announces Presentation of Additional HE2000 HIV Clinical Data: New Findings Include Improvements in Key Dendritic Cells And Increased Hematopoesis
- PRNewswire - Monday December 18, 2000
- SAN JUAN, Puerto Rico , Dec. 18 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH - news) today announced presentations of HE2000 clinical data at the Frontiers in Drug Development for Antiretroviral Therapies (HIV DART) meeting being held in San Juan, Puerto Rico December 17-21. HE2000 is the subject of
- World AIDS Day 2000 Webcast Generates Controversy And Praise...Links Teens in First Time Global Video Chat
- PRNewswire - Wednesday December 13, 2000
- WASHINGTON, Dec. 13 /PRNewswire/ -- Commemorating World AIDS Day 2000, Friday, December 1, 2000, the BeHealthyLifestyles Group, Inc. in conjunction with the AmASSI Center of Los Angeles, CA, and the ARK Foundation of Africa, conducted a first of a kind, live, global webcast event with teens discussing HIV/AIDS, from th
- Vical Notes Merck Hope of Ultimate Success for HIV Vaccine
- PRNewswire - Wednesday December 13, 2000
- SAN DIEGO, Dec. 13 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL - news) announced that an investigative HIV vaccine program was highlighted Tuesday as a key research initiative for Merck & Co. , Inc. (NYSE: MRK - news) at Merck s annual business briefing. After noting the many failures to date and the challenge
- Quest Diagnostics and Stanford University Researchers Identify New Mutation of Antiviral-Resistant HIV
- PRNewswire - Tuesday December 12, 2000
- TETERBORO, N.J., Dec. 12 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX - news), the nation s leading provider of gene-based medical testing, information and services, announced that its researchers, in collaboration with the Center for AIDS Research at Stanford University School of Medicine, have identified
- LabCorp(R) Introduces HIV GenoSure(TM), a New HIV Genotypic Resistance Assay
- PRNewswire - Tuesday December 12, 2000
- BURLINGTON, N.C., Dec. 12 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH - news; LabCorp(R)) today announced the introduction HIV GenoSure(TM), a new HIV genotypic resistance assay, to its portfolio of HIV resistance testing services. This latest offering from LabCorp, called HIV GenoSure(TM),
- C Sixty Enters Upscale Manufacturing Phase For Fullerene Based Anti-HIV Drug For Patients With AIDS: Company Announces New Board Of Directors
- PRNewswire - December 11, 2000
- TORONTO, Dec. 11 /PRNewswire/ - William Multi-Tech Inc., ( Multi-Tech ) (TSE:WIM) announced today that C Sixty Inc. ( C Sixty ) a privately held biotechnology company, in which Multi-Tech has a 40% ownership interest, has begun upscale manufacturing of its lead fullerene based drug candidate for treatment of patients w
- Progenics' HIV Therapies Featured at Scientific Conference
- PRNewswire - December 11, 2000
- ST. LUCIA, West Indies, Dec. 11 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported new findings on the Company s anti-HIV agents PRO 542 and PRO 140. The results were described Saturday at the Collaborative Research Seminar on HIV Entry and Fusion Inhibitors, a gathering of the world s leading expe
- Scientists at The Childrens Hospital, Los Angeles Begin Clinical Trial on Gene Therapy for Children Infected with HIV-1
- PRNewswire - December 8, 2000
- LOS ANGELES, Dec. 8 /PRNewswire/ -- Donald B. Kohn, M.D., and Joseph A. Church, M.D., have begun a Phase 1 clinical trial to determine if gene therapy is effective in treating children infected with HIV-1. Artificial genes have been developed which block HIV-1, the AIDS virus, from growing in human cells, said Kohn, di
- Empyrean Bioscience Announces Clinical Trials of Microbicidal Contraceptive Gel: Trials to determine if gel prevents HIV and other sexually transmitted diseases
- PRNewswire - December 8, 2000
- CLEVELAND, Dec. 8 /PRNewswire/ -- Empyrean Bioscience, Inc. (OTC Bulletin Board: EMDG) announced that the first in a series of Phase III clinical trials has begun in Brazil to determine the effectiveness of the GEDA Plus(R) microbicidal contraceptive gel in preventing the spread of HIV, other sexually transmitted disea
- New HIV/AIDS Treatment to Be Conducted at Medical Resorts International
- PRNewswire - December 5, 2000
- TORONTO, Ontario, Dec. 5 /PRNewswire/ -- Medical Resorts International, Inc. (Pink Sheets: MRINF) has entered into a 5 year contract with Aladdin Pharmaceutical to conduct clinical studies related to a new scientific breakthrough treatment for HIV and AIDS at its Hotel de Health medical facility located on
- Epimmune Licenses Gene Delivery Technologies from Valentis For HIV and HCV Vaccines
- PRNewswire - December 4, 2000
- BURLINGAME, Calif., Dec. 4 /PRNewswire/ -- Epimmune, Inc. (Nasdaq: EPMN) and Valentis, Inc. (Nasdaq: VLTS) today announced that Epimmune has licensed Valentis proprietary PINC(TM) gene delivery technology for Epimmune s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV
- AIDS Activists Picket South African Consulate: 200 Newborns Contract HIV Every Day While Government Bars Treatment: Los Angeles Consul Promises Washington Meeting
- PRNewswire - Saturday December 2, 2000
- LOS ANGELES, Dec. 2 /PRNewswire/ -- A coalition of South African and U.S. AIDS activists today picketed the Los Angeles consulate of the South African government, demanding the government immediately distribute AIDS treatment shown to drastically reduce infection in newborns. Two hundred newborns today will contract HI
- South African Ministry of Health and Pfizer Initiate Diflucan Partnership Programme: HIV/AIDS Patients to Have Access to Lifesaving Anti-fungal Medicine For as Long as They are in Need
- PRNewswire - December 1, 2000
- JOHANNESBURG, South Africa , Dec. 1 /PRNewswire/ -- The following press release was issued this morning in South Africa: The South African Ministry of Health and Pfizer Inc. today announced final approval and commencement of the South African Diflucan Partnership Programme, a unique initiative intended to benefit HIV/A
- 'HIV. Live With it. Get Tested!' Week Mobilizes Youth, Providers and Community-Based Organizations To Stem Tide of HIV Epidemic in Nation's Youth: Counseling, Testing and Access to Youth-Friendly Care Offered in Cities Hardest Hit Beginning on World AIDS Day
- PRNewswire - December 1, 2000
- NEW YORK, Dec. 1 /PRNewswire/ -- Every hour of every day, a new young person under age 21 is infected with HIV, and most don t know it until AIDS symptoms strike. To help stem the tide of the youth and HIV epidemic, beginning today -- World AIDS Day -- HIV. Live With It. Get Tested! Week (December 1-9) will reach deep
- SMLX Technologies, Inc. Announces FDA Action Update
- PRNewswire - Friday December 1, 2000
- HALLANDALE, Fla., Dec. 1 /PRNewswire/ -- SMLX (OTC Bulletin Board: SMLX - news), a bio-engineering company, announced today that the company has been served with a one count Information as the result of a government investigation concerning a former product of the company, the Rapid HIV Test Kit. The government contend
- AIDS Project Los Angeles to Distribute 10,000 AIDS Awareness Posters And Madonna CDs on World AIDS Day, December 1, 2000: Los Angeles County High School Students to Receive World AIDS Day Package
- PRNewswire - Thursday November 30, 2000
- LOS ANGELES, Nov. 30 /PRNewswire/ -- Of the 34.3 million people worldwide, 1.3 million children 15 and under are living with HIV and AIDS around the world today according to 1999 estimates by UNAIDS . In the United States , it is estimated that more than 40,000 Americans are infected each year. Half of those infection
- On the Eve of World AIDS Day, Surgeon General's HIV/AIDS Assessment for America: Good ... Bad
- PRNewswire - Thursday November 30, 2000
- WASHINGTON, Nov. 30 /PRNewswire/ -- On the eve of World AIDS Day, Assistant Secretary for Health and Surgeon General David Satcher said that although infections may have fallen, HIV/AIDS still represents a severe and ongoing crisis in America, particularly for men in communities of color. The good news is that HIV infe
- World AIDS Day Report: Boehringer Ingelheim Announces Step Forward in Making its Anti-HIV Drug More Accessible in Developing Countries
- PRNewswire - Thursday November 30, 2000
- INGELHEIM, Germany , Nov. 30 /PRNewswire/ -- Boehringer Ingelheim announced that the Republic of Congo (Congo Brazzaville) is the first country to benefit from the company s offer to provide its anti-HIV drug VIRAMUNE® (nevirapine) free of charge for a period of five years to developing countries for use in the prevent
- amfAR and Netcentives Join Forces in Campaign to Raise $500,000 in Online Donations for AIDS Research
- PRNewswire - Thursday November 30, 2000
- NEW YORK and SAN FRANCISCO, Nov. 30 /PRNewswire/ -- The American Foundation for AIDS Research (amfAR) and Netcentives Inc., a leading provider of technology and services for loyalty and direct marketing, are teaming up and challenging the public to help them raise $500,000 for AIDS research with a campaign that awards
- Antex Strengthens STD Vaccine Patent Portfolio; Patents Filed on Chlamydia Trachomatis Proteins
- PRNewswire - Thursday November 30, 2000
- GAITHERSBURG, Md., Nov. 30 /PRNewswire/ -- Antex Biologics Inc. (Amex: ANX - news) today announced that it has filed patent applications for two additional novel proteins of Chlamydia trachomatis, the leading sexually transmitted disease in the US and worldwide. These two proteins are being evaluated as vaccine candida
- The Healthy Living Project Sponsors HIV/AIDS Workshop on World AIDS Day: The Healthy Living Project, MCC's MOMobile Program, Women's Christian Alliance, and HOPE Worldwide Are Working Together to Educate Philadelphia Neighborhoods About HIV/AIDS
- PRNewswire - November 29, 2000
- PHILADELPHIA, Nov. 29 /PRNewswire/ -- The workshop will be held at Women s Christian Alliance (WCA), in the main auditorium of the Community Family Center at 1610 N. Broad St., from 11 a.m. to 2 p.m. on December 1, 2000. Lunch and childcare will be provided to those attending. From 2 p.m. to 5 p.m., Hope worldwide will
- India Fights AIDS: Mobilizing Men and Educating Communities For World AIDS Day December 1, 2000: AFXB-Sponsored Events in Jodhpur, India, Include Tractor-Trailer Rally Leading Thousands from the Mehrangarh Fort on the Edge of the Desert Throughout This Major Tourist City.
- PRNewswire - Wednesday - November 29, 2000
- JODHPUR, India , Nov. 29 /PRNewswire/ -- Located on the eastern border of the Thar Desert, dust storms are common here. However, a different type of storm is about to hit Jodhpur on World AIDS Day, one the city may not be prepared for! Jodhpur is located in northern India state of Rajasthan, where over 50% of the worki
- Chicago-Based Female Health Company Battles African AIDS Crisis: World AIDS Day Marks Expansion of Successful Female Condom Program in Namibia
- PRNewswire - November 28, 2000
- CHICAGO, Nov. 28 /PRNewswire/ -- Chicago s concrete jungle may be worlds away from the African continent, but the two places have something in common. The Windy City is home to the only U.S. company leading the way in HIV/AIDS prevention from a woman s perspective. Women in sub-Saharan Africa and other developing world
- ProdiGene Receives National Institutes of Health Grant to Study Development Of Edible AIDS Vaccine
- PRNewswire - Tuesday November 28, 2000
- COLLEGE STATION, Texas, Nov. 28 /PRNewswire/ -- Research on development of an edible vaccine for AIDS produced from transgenic plants will be funded through an Innovation Grant from the National Institutes of Health and conducted by ProdiGene, a biopharmaceutical and industrial protein company located in College Statio
- Project Inform Chooses iMetrikus to Launch Online Health Management Tool; AIDS Service Organization Adds MyHealthChannel.com Program to Advocacy Agenda
- PRNewswire - Tuesday November 28, 2000
- CARLSBAD, Calif., Nov. 28 /PRNewswire/ -- iMetrikus today announced a partnership with Project Inform, a national non-profit, community-based organization working to end the AIDS epidemic. The partnership with Project Inform will create a co-branded MyHealthChannel Web site for people with HIV/AIDS and their caregivers
- BET Launches 'Rap-It-Up' Campaign Addressing HIV/AIDS: Kaiser Family Foundation, Magic Johnson Foundation, LIFEBeat And Cable Positive Join Network in National Awareness Initiative
- PRNewswire - Tuesday November 28, 2000
- LOS ANGELES, Nov. 28 /PRNewswire/ -- In an unprecedented partnership between philanthropic foundations, corporate entities, media outlets and community-conscious organizations, Black Entertainment Television (BET) has announced the creation of Rap-It-Up, a multi-faceted national awareness and call-to-action campaign ad
- Progenics Starts Phase II Trial of Pro 542 in HIV Infected Children: Results of Phase I/II Pediatric Trial Published The Journal of Infectious Diseases
- PRNewswire - Tuesday November 28, 2000
- TARRYTOWN, N.Y., Nov. 28 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced that treatment of HIV positive pediatric patients had begun in a Phase II study of PRO 542, the Company s most clinically advanced HIV inhibitor. The Company also announced the publication of a scientific arti
- UPMC Health System Commemorates World Aids Day With Free Walk-In HIV Testing, Counseling
- PRnewswire - November 27, 2000
- PITTSBURGH, Nov. 27 /PRNewswire/ -- In conjunction with the 13th annual World AIDS Day, UPMC Health System will offer free HIV testing and counseling from 10 a.m. until 2 p.m. on Friday, Dec. 1. These services will be available at UPMC s HIV treatment arm, the Pittsburgh AIDS Center for Treatment (PACT), located in Sui
- Virax's HIV Treatment Vaccine Enters Human Trials:
- PRNewswire - Monday November 27, 2000
- MELBOURNE, Australia , Nov. 27 /PRNewswire/-- Virax Holdings Limited (ASX:VHL) announced today ethics committee approval has been received so removing the last hurdle to the start of a human clinical trial of a vaccine to treat people recently infected with HIV. The trial, to be conducted in Melbourne and Sydney, will
- From Harlem to Soweto: The Black Church Speaks Out On AIDS! Friday, December 1, 2000 World AIDS Day: World AIDS Day Program Stretches Across The Globe With A Live Simulcast Broadcasting To 30 African Countries Location: St. Marks United Methodist Church (137th Street/Edgecombe Ave.) Manhattan, 9:30 a.m. (EST)
- PRNewswire - Monday November 27, 2000
- NEW YORK, Nov. 27 /PRNewswire/ -- AIDS is the number one cause of death for African-American adults ages 25-44. The Sub-Saharan Africa is the hardest hit in the world, with the greatest concentration of HIV/AIDS. South Africa has the world s highest rate of infection with HIV. It is projected that within the next 5-10
- Decision Resources Study Evaluates Market Drivers for Current and Emerging Anti-HIV Therapies and Forecasts Potential Sales in Global Markets Through 2009
- PRNewswire - Monday November 27, 2000
- WALTHAM, Mass., Nov. 27 /PRNewswire/ -- Decision Resources, Inc, announces the publication of HIV 2000-Major and Emerging Markets. Increasing prevalence, persistent and resistant infection, and poor adherence continue to make HIV/AIDS a significant pharmaceutical market fraught with unmet needs. In the seven major mark
- VX-175, Vertex and Glaxo Wellcome's HIV Protease Inhibitor, Begins Phase III Clinical Trials: Once Daily Regimen Investigated
- PRNewswire - Monday November 27, 2000
- CAMBRIDGE, Mass., Nov. 27 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news) announced today that VX-175, an HIV protease inhibitor discovered by Vertex and licensed by Glaxo Wellcome , has entered Phase III clinical trials. VX-175 (also known as GW433908) is a prodrug of the HIV protease inhibit
- Vascular Access Applauds Recent Passage of Needlestick Safety Legislation
- PRNewswire - Wednesday November 22, 2000
- CINCINNATI, Nov. 22 /PRNewswire/ -- Ethicon Endo Surgery, Vascular Access, a Johnson & Johnson company, embraces the recent passage of the Needlestick Safety and Stick Safety legislation to protect the health of the 8 million healthcare workers in the United States . The bill will require all healthcare faci
- Independent HIV Expert Committee Recommends Completion of Study of REMUNE(TM) Plus Antiretroviral Drugs in Order to Solidify the Findings DSMB Satisfied With Conduct and Analysis of Spanish Trial (STIR-2102 Study) With REMUNE (HIV-1 Immunogen)
- PRNewswire - Tuesday November 21, 2000
- CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the trial in Spain of REMUNE(TM) plus antiretroviral drugs in patients infected with HIV continue to its conclusion in May 2001. This d
- Independent HIV Expert Committee Recommends Completion of Study of REMUNE(TM) Plus Antiretroviral Drugs in Order to Solidify the Findings DSMB Satisfied With Conduct and Analysis of Spanish Trial (STIR-2102 Study) With REMUNE (HIV-1 Immunogen)
- PRNewswire - Tuesday November 21, 2000
- CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the trial in Spain of REMUNE(TM) plus antiretroviral drugs in patients infected with HIV continue to its conclusion in May 2001. This d
- Serologicals Corporation to Participate in Centers for Disease Control's HIV/HCV Risk Factor Study
- PRNewswire - Monday November 20, 2000
- ATLANTA, Nov. 20 /PRNewswire/ -- Serologicals Corporation (Nasdaq: SERO - news) today announced that it has been selected to participate in a Centers for Disease Control and Prevention (CDC) HIV/HCV (Hepatitis C) Risk Factor Study. The CDC, in collaboration with Boston Biomedica, Inc. (Nasdaq: BMII - news) seeks to ana
- MTV Networks Announces Global Programming Line-Up For World AIDS Day, December 1st, 2000
- PRNewswire - Monday November 20, 2000
- NEW YORK and LONDON, Nov. 20 /PRNewswire/ -- MTV: Music Television, the world s largest television network, today announced their global programming schedule for World AIDS Day on December 1, 2000. Heading the line-up are two world premieres of original productions, Staying Alive 2, hosted by superstar Ricky Martin and
- Gospel Artists, U.S. Surgeon General and Congressional Black Caucus Launch National Campaign In Response to HIV/AIDS Epidemic in the African American Community
- PRNewswire - Thursday November 16, 2000
- WASHINGTON, Nov. 16 /PRNewswire/ -- Gospel music artists and leaders joined with the Office of the Surgeon General and the Congressional Black Caucus today to announce a campaign to help address the HIV/AIDS epidemic in the Black community. ONE VOICE: Gospel Artists Respond to AIDS campaign is led by Rev. Yvette Flunde
- New Tablet is the First to Combine Three Medications to Treat HIV: Latest FDA drug approval may simplify therapy for some patients with HIV - Trizivir combines 3 drugs into 1 pill that is taken just twice a day
- PRNewswire - Wednesday November 15, 2000
- LAVAL, Quebec, Nov. 15 /PRNewswire/ - BioChem Pharma Inc.(NASDAQ: BCHE - news; TSE: BCH - news) announced today that Trizivir , a new product that combines three anti-HIV medicines into one single tablet, has been approved by the United States Food and Drug Administration.
- Trinity Medical Group USA Announces Public Availability of REMUNE(TM) Treatment in Thailand
- PRNewswire - Wednesday November 15, 2000
- SAN RAFAEL, Calif., Nov. 15 /PRNewswire/ -- The first open label availability in Southeast Asia of Immune Based Therapy (IBT) for humans infected with HIV has been approved by the government of Thailand . Up to 10,000 individuals in this program may receive treatment with REMUNE provided they have certain levels of imm
- Office of the Surgeon General: HIV/AIDS Poses an Explosive And Serious Threat to American Indian and Alaska Native Communities
- PRNewswire - Wednesday November 15, 2000
- ST. PAUL, Minn., Nov. 15 /PRNewswire/ -- American Indians and Alaska Natives are experiencing an increasing rate of HIV/AIDS that, if left unchecked, poses a serious health threat that could devastate Native American communities in the United States , a U.S. government official said today. The number of American I
- Glaxo Wellcome New Tablet is the First to Combine Three Medications To Treat HIV: Latest FDA drug approval may simplify therapy for some patients with HIV. Trizivir combines 3 drugs into 1 pill that is taken just twice a day.
- PRNewswire - Wednesday November 15, 2000
- RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire/ -- Trizivir , a new product that combines three anti-HIV medicines into one single tablet, has been approved by the Food and Drug Administration. This marks an important advance for dosing of combination drug regimens. Patients for whom Trizivir is prescribed will now
- Veritas Medicine Launches Comprehensive Online Clinical Trials and Treatment Resource for Chronically Ill Patients and Their Physicians: Personalized Matching to 1,200 Trials is Augmented With Trusted Information From Harvard- and Tufts-Affiliated Physicians; Agreements with Leading Health-Related Sites Enable Access By Millions in Need
- PRNewswire - Wednesday November 15, 2000
- CAMBRIDGE, Mass., Nov. 15 /PRNewswire/ -- Millions afflicted with chronic illnesses ranging from breast cancer and hepatitis C , to AIDS/HIV and leukemia, now have access to the most comprehensive, reliable clinical trials and treatment information through www.veritasmedicine.com or via premiere health-related sites.
- Stressgen announces ruling in European patent opposition proceedings
- PRNewswire - Tuesday November 14, 2000
- MUNICH, GERMANY, Nov. 14 /PRNewswire/ - Stressgen Biotechnologies Corporation (TSE: SSB - news) announced today a ruling from the European Patent Office, Opposition Division (OD) related to European Patent 0419569B1 filed by the Whitehead Institute. This patent represented the earliest filings from Whitehead covering t
- Biosyn Announces New Data Indicating SAVVY(R) Vaginal Microbicide is Highly Acceptable Formulation Among Women
- PRNewsiwre - Tuesday November 14, 2000
- PHILADELPHIA, Nov. 14 /PRNewswire/ -- Biosyn, Inc. announced today that SAVVY(TM) vaginal microbicide, a product in development for the prevention of sexually transmitted diseases (STDs), including HIV, was found to be a highly acceptable formulation among women in a Phase I clinical study. SAVVY is a vaginally applied
- Trinity Medical Group USA Announces Continuation of HIV Clinical Trial
- PRnewswire - Monday November 13, 2000
- SAN RAFAEL, Calif., Nov. 13 /PRNewswire/ -- The Clinical Trial using REMUNE(TM) as a treatment for HIV in Thailand has been approved for an additional two years. The Study, known as Protocol 2101B, will become one of the longest scientific examinations of Immune Based Therapy (IBT) for humans infected with HIV. The app
- The California Fashion Industry Friends of AIDS Healthcare Foundation to Honor Designer Nicole Miller in Remembrance of Worlds AIDS Day 2000: Miller to Debut First Ever Men's Collection at Black Tie Gala and Fashion Show Benefiting Nation's Largest HIV/AIDS Medical Provider - Cheryl Tiegs to Receive First Annual 'M-A-C Cosmetics Fashion Icon Award'
- PRNewswire - Friday November 10, 2000
- LOS ANGELES, Nov. 10 /PRNewswire/ -- The California Fashion Industry Friends of AIDS Healthcare Foundation (formerly known as California Fashion Industry Friends of AIDS Project Los Angeles) will honor award-winning American designer NICOLE MILLER Wednesday, November 29th at its 11th annual black tie gala and fundraise
- New Test Can Predict Response to Cancer Treatment; Diagnostic Tool From Virco Could Significantly Improve Cancer Treatment
- PRNewsiwre - Thursday November 9, 2000
- BALTIMORE, Nov. 9 /PRNewswire/ -- A new test can tell if cancer patients are likely to respond to the most common drug treatment, according to results of a clinical trial published today in the New England Journal of Medicine. Virco, an international biotechnology company specializing in the diagnosis and management of
- Healthcare Workers Are Now Closer to a Safer Workplace
- PRNewswire - Thursday November 9, 2000
- LAKEWOOD, N.J., Nov. 9 /PRNewswire/ -- The government of the United States has taken the final step towards making the workplace a safer place for healthcare workers. Between 800,000 and 1 million healthcare workers are accidentally stuck by a needle each year. Once stuck, contracting
- Stressgen scientists and key MIT collaborators present at International Symposium on Heat Shock Proteins in Biology and Medicine: Data Reinforces Utility of Heat Shock Protein Fusions as Platform for Development of Novel Immunotherapeutics
- PRNewswire - Wednesday November 8, 2000
- WOODS HOLE, MA, Nov. 8 /PRNewswire/ - Stressgen Biotechnologies Corp. (TSE: SSB - news) announces the presentation of preclinical data on the immune response to the HspE7 fusion protein at the International Symposium on Heat Shock Proteins in Biology and Medicine, a scientific conference sponsored by Harvard Medical Sc
- Patients Exposed to HIV and Hepatitis Through Questionable Medical Equipment Leads to Filing of Class Action Lawsuit by Thurswell, Chayet & Weiner Against W.A. Foote Memorial Hospital, Inc. in Jackson, Michigan
- PRNewswire - Monday November 6, 2000
- SOUTHFIELD, Mich., Nov. 6 /PRNewswire/ -- Southfield-based personal injury law firm Thurswell, Chayet & Weiner is representing former patients of W.A. Foote Memorial Hospital, Inc. in Jackson, Michigan, who were possibly exposed to HIV and Hepatitis during minor outpatient scope procedures. According to the hospita
- StressGen initiates HspE7 Phase III trial in HPV-related anal dysplasia: CDC reports HPV second only to HIV in US STD related healthcare costs
- PRNewswire - November 6, 2000
- VICTORIA, BC, Nov. 6 /PRNewswire/ - StressGen Biotechnologies Corp. (TSE: SSB) announced today that it has initiated patient treatment in a Phase III clinical trial to investigate HspE7 as a novel immunotherapeutic for anal dysplasia (AIN) caused by the human papilloma virus ( HPV ). HPV is
- AVAX Technologies Awarded Patent on New Vaccine Delivery Platform: Patent Covers Use of Non Replicative, Defective Viruses as Delivery Mechanisms for the Prevention or Treatment of HIV, Herpes and Other Viral Diseases -
- PRNewswire - November 6, 2000
- KANSAS CITY, Mo., Nov. 6 /PRNewswire/ --AVAX Technologies, Inc. (Nasdaq: AVXT) today announced that it has been granted U.S. Patent No. 6,140,114 from the U.S. Patent and Trademark Office entitled Defective viral vaccine particles obtained in vivo or ex vivo. David Klatzmann, M.D., Ph.D. and Jean-Loup Salzmann, M.D., P
- Hemispherx Biopharma Announces Phase II Clinical HIV Results At American Society of Microbiology
- PRNewswire - November 2, 2000
- PHILADELPHIA, Nov. 2 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said that results of a Phase II study of the investigational drug Ampligen(R) would be first presented at the American Society of Microbiology Conference in Memphis, Tennessee, on November 3 and 4, 2000. The U.S. based monotherapy clinic
- Advanced Viral Research to Present New Data at Upcoming HIV Conferences
- PRNewswire - November 2, 2000
- NEW YORK, Nov. 2 /PRNewswire/ -- Advanced Viral Research announced today that new data on Reticulose, their flagship product for the treatment of HIV and other viral diseases will be presented at the National AIDS Treatment Advocacy Conference held by the National Minority AIDS Council in Dallas Texas, November 9th to
- The Immune Response Corporation Announces Arbitration Proceedings And Dispute Over Exclusion of Clinical Investigators and Sponsor Comments In The Publication of Clinical Trial Data Of REMUNE(TM) (HIV-1 Immunogen)
- PRNewswire - October 31, 2000
- CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it had initiated binding arbitration proceedings in a disagreement with the University of California San Francisco (UCSF) and a member of its faculty, Dr. James Kahn. The principle basis for the arbitration is
- Triangle Pharmaceuticals Reports Marked Anti-Hepatitis B Activity of Coviracil(R)(Emtricitabine)in Phase I/II Dose-Selection Trial: Data Presented at the American Association for the Study of Liver Diseases Meeting in Dallas
- PRNewswire - October 30, 2000
- DURHAM, N.C., Oct. 30 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) today reported on the anti- hepatitis B virus (HBV) activity of Coviracil(R) (emtricitabine) in a Phase I/II dose-selection trial involving patients chronically infected with HBV. The data are being presented at the 51st Annual Meeting
- Nation's First African-American AIDS Think Tank Opens Headquarters in Los Angeles: State-of-the-Art Facility Offers Skills Building and AIDS Advocacy Training for African-Americans
- PRNewswire - October 27, 2000
- LOS ANGELES, Oct. 27 /PRNewswire/ -- The African-American AIDS Policy and Training Institute (AAAPTI), the nation s first and only think tank dedicated to studying the policies and science of AIDS among African-Americans, will christen new headquarters at a grand opening ceremony here today. The new facility includes t
- AHFC and Four A's Receive $572,600 AIDS Grant
- PRNewswire - October 27, 2000
- ANCHORAGE, Alaska, Oct. 27 /PRNewswire/ -- The Alaska Housing Finance Corporation (AHFC) will receive $572,600 to continue providing housing services for persons with HIV/AIDS in cooperation with its sponsor, the Alaskan AIDS Assistance Association (Four A s). Alaska was one of 17 states recently awarded $23.6 million
- New Cancer Drug - Invented in Australia
- PRNewswire - October 26, 2000
- MELBOURNE, Australia , Oct. 26 /PRNewswire/ -- Sydney researchers at the University of New South Wales (UNSW) have invented a new cancer drug that starves tumours instead of poisoning them. Melbourne pharmaceutical company IDT Australia Ltd will manufacture the drug and work to capture the commercial benefit for Austra
- Calypte Applauds the Passage of Needlestick Safety and Prevention Bill
- PRNewswire - October 26, 2000
- ALAMEDA, Calif., Oct. 26 /PRNewswire/ -- On October 26, 2000 the U.S. Senate joined the fight to protect America s health care workers by passing a U.S. House of Representatives bill, H.R. 5178, the Needlestick Safety and Prevention Act of 2000. H.R. 5178 has strong bipartisan support and unanimously passed both chambe
- As Senate Passes Needlestick Legislation ... Health Care Workers Say Bill Will Save Thousands of Lives: Victims Infected with HIV, Hepatitis C Available to Tell Their Stories
- PRNewswire - October 26, 2000
- WASHINGTON, Oct. 26 /PRNewswire/ -- Members of the nation s largest health care union say passage of bipartisan legislation in the U.S. Senate today will protect health care workers from deadly needlestick injuries that can spread HIV and hepatitis C . This bill will save the lives of thousands of health care w
- Virco First to use Artificial Intelligence to Unravel the Mystery of HIV Drug Resistance: Neural Networks Make Virco Resistance Testing Even More Accurate
- PRNewswire - October 26, 2000
- GLASGOW, Scotland, Oct. 26 /PRNewswire/ -- Data presented today at the 5th International Congress on Drug Therapy in HIV Infection for the first time revealed the mutations in the genetic code of HIV that make the virus resistant to the HIV drug, d4T (
- Sex-Based Differences Emerging in Pain, Addiction and STDs: Findings To Be Presented at Society for Women's Health Research's 10th Annual Meeting
- PRNewswire - Wednesday October 25, 2000
- WASHINGTON, Oct. 25 /PRNewswire/ -- Gender plays a major role in the way we experience and respond to various treatments for pain, addiction, and sexually transmitted diseases, according to recent research. These and other emerging trends in sex-based research will be presented and discussed at the Society for Women s
- Virco Commences HIV Therapeutic Drug Monitoring Service
- PRNewswire - October 24, 2000
- BALTIMORE, Oct. 24 /PRNewswire/ -- A new test for the simultaneous determination of levels of all the HIV drugs currently in widespread use is now available from Virco. The test, named VircoPK(TM) is rapid and more accurate and reliable than other tests for measuring drug levels. It can be used in conjunction with Virc
- No Genotypic Resistance Detected In Clinical Trials Through 48 and 108 Weeks With Abbott Laboratories' Kaletra(TM) (Lopinavir/Ritonavir) in Patients Without Previous HIV Therapy
- PRNewswire - October 24, 2000
- GLASGOW, Scotland, Oct. 24 /PRNewswire/ -- Data presented at the Fifth International Congress on Drug Therapy in HIV Infection in Glasgow show that to date, patients new to HIV therapy have not developed genotypic resistance to Abbott Laboratories (NYSE: ABT) protease inhibitor (PI),
- M*A*C Cosmetics Announces Donation for HIV/AIDS Projects in Southern Africa; M*A*C AIDS Fund Has Donated more than $750,000 to Fight AIDS in Africa
- PRNewswire - October 24, 2000
- NEW YORK, Oct. 24 /PRNewswire/ -- The M.A.C. AIDS Fund donated $250,000 to UNDP to support seven grassroots projects helping people living with HIV/AIDS and promoting HIV/AIDS awareness in six southern African countries. John Demsey, President of M.A.C. Cosmetics, announced the donation at the Fourth Annual Race Agains
- First-ever National HIV/AIDS Specialist Physicians Group Organizes To Advocate for Expanded Access to Care for HIV/AIDS Patients: Media Interviews Availability with R. Scott Hitt, MD
- PRNewswire - October 24, 2000
- LOS ANGELES, Oct. 24 /PRNewswire/ -- The American Academy of HIV Medicine (AAHIVM) reached an important milestone this month. As of October, more than 500 physicians representing approximately 100,000 HIV/AIDS patients nationwide have joined the new organization. AAHIVM was launched in January by a group of physicians
- 'HIV. Live With It. Get Tested!' Provider Conference to Underscore Need for HIV Counseling and Testing of Youth: More than 500 NYC Providers and Youth to Attend - - New York Health Commissioner Stresses Crisis of HIV in Youth -
- PRNewswire - October 24, 2000
- NEW YORK, Oct. 24 /PRNewswire/ -- The Adolescent AIDS Program at Montefiore Medical Center today convenes Gettin Busy Youth and HIV: A Conference and Call to Action for Providers and Youth in New York City. Featuring a key note address by New York State Health Commissioner Antonia Novello, MD, DPH, this multidisciplina
- Children Affected By AIDS in Africa Get Support From Marathon Runner
- PRNewswire - October 23, 2000
- NEW YORK, Oct. 23 /PRNewswire/ -- New York City Marathon Runner Renee Stene is leading a drive to support AIDS orphans in Africa and the Francois-Xavier Bagnoud s GLOBAL ACTION FOR ORPHANS CAMPAIGN by signing up pledges for her run on November 5th. Renee s efforts will help raise awareness in the world s biggest city o
- Vertex and Glaxo Wellcome's New Anti-HIV Medicine, Agenerase(TM) (Amprenavir), Approved in the European Union
- PRNewswire - October 23, 2000
- CAMBRIDGE, Mass., Oct. 23 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that its collaborator, Glaxo Wellcome , has received approval from the European Commission to market the HIV protease inhibitor (PI) Agenerase (amprenavir), in all 15 c
- AIDS Vaccine One Year From First Efficacy Analysis: VaxGen Trials Receive 4th Positive Safety Review
- PRNewswire - October 23, 2000
- BRISBANE, Calif., Oct. 23 /PRNewswire/ -- VaxGen (Nasdaq: VXGN) announced today that it is now one year away from its first opportunity to determine if its preventive HIV/AIDS vaccine is effective. The milestone was reached when VaxGen s Phase III clinical trials received a positive safety review that allows the trials
- Patients Remain on Viracept-Based HAART Longer than Indinavir-Based HAART (New Swiss Cohort Study data): The following press release was issued today by F. Hoffman-La Roche Ltd.:
- PRNewswire - October 23, 2000
- GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- New data released today at the 5th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland, have shown that patients stay significantly longer on Viracept (nelfinavir)-based initial HAART regimens than on indinavir-based initial HAART regimens.
- Marinol(R) (dronabinol) May Reduce Nausea and Vomiting Associated with HIV Therapy
- PRNewswire - October 23, 2000
- GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- New study findings show that 85% (23/27) of HIV/AIDS patients who added MARINOL(R) (dronabinol) to their current antiretroviral therapy had a 50% improvement in symptoms of nausea and vomiting. MARINOL is indicated as an appetite stimulant for patients with AIDS-associated was
- Virco First to Introduce Drug-Specific Biological Cut-Offs for Its HIV Resistance Tests
- PRNewswire - Ocotber 23, 2000
- GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- Data presented today at the 5th International Congress on Drug Therapy in HIV Infection identified and discussed new drug-specific, biological cut-off values developed by Virco for its HIV drug resistance tests. These will tell clinicians instantly whether their patient s viru
- Call to Action - Roche Advocates Development of HIV Drug Potency Guidelines To Help Physicians Make Optimal Treatment Decisions
- PRNewswire - October 23, 2000
- GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- F. Hoffmann-La Roche , makers of the anti-HIV agents Fortovase (R) ( saquinavir ) and Viracept (R) (nelfina
- Roche HIV Protease Inhibitor Saquinavir Shows Greater In Vitro Potency Than New Drug Lopinavir
- PRNewswire - October 23, 2000
- GLASGOW, Scotland, Oct. 23 /PRNewswire/ -- Roche has announced the results of in vitro laboratory experiments showing that the Roche HIV protease inhibitor (PI) saquinavir is more potent than the new PI, lopinavir . The study, presented at the 5th International Congress on Drug Therapy in
- Advanced Viral Research Persues Clinical Development of Riticulose to Treat HIV Drug Resistance
- PRNewswire - October 20, 2000
- NEW YORK, Oct. 20 /PRNewswire/ -- Further clinical research into HIV drug resistance along with aggressive advocacy by growing numbers of AIDS activists has created a consensus amongst many prominent AIDS treatment activists and clinicians that Riticulose, the flagship product of Advance Viral Research may be the best
- IAVI Encouraged by Results of AIDS Vaccine Study in Monkeys; Calls for Greater Private Sector Commitment, More Rapid Movement of Vaccine Candidates into Human Trials
- PRNewswire - Thursday October 19, 2000
- NEW YORK, Oct. 19 /PRNewswire/ -- Seth Berkley, MD, President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), issued the following the statement in response to the publication in Science of a study showing promising results in monkeys for a DNA-based AIDS vaccine augmented with interleu
- McKessonHBOC MedManagement Lands Exclusive Contract for Pharmacy Management Services With Nation's Largest HIV/AIDS Medical Provider: AIDS Healthcare Foundation Clinic Patients to Benefit from On-site Pharmacy Services: Patient-Focused Program Aims to Boost Adherence To Medication Regimens
- PRNewswire - Thursday October 19, 2000
- MINNEAPOLIS and LOS ANGELES, Oct. 19 /PRNewswire/ -- The nation s largest HIV medical services organization today opened its first on-site pharmacy at a gala ceremony at the downtown Los Angeles AHF Healthcare Center. This event launches an innovative effort between two diverse healthcare industry leaders: MedManagemen
- Hope for African Children Developing Programs for Children Affected by HIV/AIDS: The Gates Foundation Supports Partnership With $1 Million Planning Grant
- PRnewswire - October 19, 2000
- WARWICK, R.I., Oct. 19 /PRNewswire/ -- Hope for African Children, a partnership of international development and relief organizations, has received a $1 million grant from the Bill & Melinda Gates Foundation to develop a pioneering pan-African initiative designed to deliver essential services and support to the mil
- Cuomo Awards $23.6 Million in HUD Grants to Help Thousands With HIV/AIDS and Their Families in 17 States
- PRnewswire - October 18, 2000
- WASHINGTON, Oct. 18 /PRNewswire/ -- U.S. Housing and Urban Development Secretary Andrew Cuomo today awarded $23.6 million to programs in 17 states to provide housing and related support services to more than 2,700 low-income people with HIV/AIDS and their families. The grants are part of HUD s Housing Opportunities for
- The American Academy of Dermatology: Sexually Transmitted Diseases -- Treating America's Hidden Epidemic
- PRNewswire - Wednesday October 18, 2000
- NEW YORK, Oct. 18 /PRNewswire/ -- Teenagers are bombarded with images of sex on a daily basis. Whether it be television, movies, music, or magazines, the joy of sex is often glorified while the consequences are rarely addressed. Yet what teenagers need to know is that most sexually transmitted diseases are difficult to
- Verizon Wireless Celebrates 2nd Year as Official Wireless Sponsor for AIDS Walk Arizona New Customers Receive 100 Free Minutes With AIDS Walk Registration
- PRNewswire - Wednesday October 18, 2000
- PHOENIX, Oct. 18 /PRNewswire/ -- Verizon Wireless today announced that it is the official wireless sponsor for the 13th annual AIDS Walk Arizona to be held on Sunday, Nov. 5. As part of its sponsorship, customers who register for the walk by Oct. 25 at any Verizon Wireless store will receive an additional 100 free minu
- Progenics Awarded $6.0 Million for HIV Therapy and Vaccine Programs
- PRNewswire - Tuesday October 17, 2000
- TARRYTOWN, N.Y., Oct. 17 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) today announced that it had been awarded approximately $6.0 million from the National Institutes of Health (NIH) for the development of novel therapies and vaccines for HIV infection. The awards consist of a research grant fo
- Maintaining Weight May Improve Survival and Quality of Life for People Living with HIV and Cancer: Researchers Recommend Early Weight-Loss Intervention at ADA Symposium
- PRNewswire - October 16, 2000
- DENVER, Oct. 16 /PRNewswire/ -- Weight loss and HIV wasting have a direct impact on survival in cancer and HIV/AIDS patients. Data supporting these findings, as well as methods for early intervention to prevent weight loss, were discussed here today at a symposium, Evidence-Based Management of Disease-Related Weight Lo
- AIDS Treatment Activists, Clinicians See FDA IBT Meeting as Historic Development
- PRNewswire - Monday October 16, 2000
- NEW YORK, Oct. 16 /PRNewswire/ -- The FDA is holding a meeting today in Washington D.C. to explore the problems that have surrounded the regulatory review of immune based therapies for HIV. Over the past two years AIDS Treatment Activists from around the country have advocated within the FDA for a revision of regulator
- Ampligen, IL-2, Other IBT's to be Discussed at FDA Meeting in D.C.
- PRNewswire - Monday October 16, 2000
- NEW YORK, Oct. 16 /PRNewswire/ -- A much needed and long overdue meeting has been scheduled for Oct. 16 by the FDA Antiviral Committee to discuss Immune Based Therapies. This much anticipated effort by the FDA provides an encouraging signal to the pharmaceutical industry and biotech companies that meaningful progress i
- FDA to Receive Public Testimony on Immune Based Therapies for HIV
- PRNewswire - Monday October 16, 2000
- NEW YORK, Oct. 16 /PRNewswire/ -- Over the past 14 months, AIDS treatment activists, many of whom are members of The HIV Immune Based Therapy Working Group have placed pressure on the Food and Drug Administration regarding the FDA process, procedures and review of immune based therapies for the treatment of HIV disease
- Government Will Soon Save Healthcare Workers' Lives
- PRNewswire - October 13, 2000
- LAKEWOOD, N.J., Oct. 13 /PRNewswire/ -- Healthcare workers might not have to fear losing their lives saving others, but it is up to the government of the United States to make it happen. Between 800,000 and 1 million healthcare workers are accidentally stuck by a needle each year. Once stuck, contracting
- World Health Organization Commission on Macroeconomics and Health Receives $1 Million From the Bill & Melinda Gates Foundation
- PRNewswire - October 12, 2000
- BOSTON, Oct. 12 /PRNewswire/ -- The Commission on Macroeconomics and Health (CMH) will expand its work in improving public health with a recent gift of $1 million from the Bill & Melinda Gates Foundation. The CMH, launched by the Director General of the World Health Organization in January 2000, studies the intrica
- MAC Cosmetics and Mary J. Blige Take the World Stage To Talk About HIV and AIDS in Africa: MAC Cosmetics' VIVA GLAM III Spokesperson Mary J. Blige to Perform on October 23rd at the United Nations General Assembly Hall at the Race Against Poverty Awards: MAC Cosmetics Has Donated More Than $750,000 To Fight Aids in Africa This Year Through the MAC Aids Fund
- PRNewswire - October 12, 2000
- NEW YORK, Oct. 12 /PRNewswire/ -- On Monday, October 23, 2000, the United Nations Development Programme (UNDP) will hold its Fourth Annual Race Against Poverty Awards at the United Nations General Assembly from 6:00 p.m. to 8:00 p.m. Grammy Award-winning superstar and MAC Cosmetics VIVA GLAM III spokesperson Mary J. Bl
- University of Edinburgh Scientist Funded For Studies on Controversial Blood Borne Viruses: The Consortium for Plasma Science Awards Research Fellowship
- PRNewswire - October 11, 2000
- EDINBURGH, Scotland, Oct. 11 /PRNewswire/ -- University of Edinburgh scientist, Peter Simmonds, Ph.D., MRCPath, today received a Consortium for Plasma Science Fellowship to support his ground-braking research on the evolution, epidemiology, and potential pathogenicity of a controversial group of novel, human blood born
- HIV/AIDS is 'Invisible Issue' in Presidential Campaign Says the International Association of Physicians in AIDS Care: --Gore Position on Needle Exchange Termed 'Violation Of Human Right to Tools and Strategies That Can Save Lives' -- Bush Said to 'Lack Vision to Face Social, Political, And Economic Challenges of HIV/AIDS as Human Security Threat'
- PRNewswire - October 11, 2000
- CHICAGO, Oct. 11 /PRNewswire/ -- AIDS is an invisible issue in the 2000 presidential campaign, with neither candidate articulating a vision or strategy for combating an epidemic labeled by the US government and the United Nations as threats to human security. So says the International Association of Physicians in AIDS
- Development of New Anti-TB Treatments Affordable in Worst-Hit Countries is Aim of New, Global Public-Private Partnership Global Alliance for TB Drug Development Commits to Delivering Its First New Drug : Total Funding Expected to Exceed US$150 Million; Gates and Rockefeller Foundations Announce Commitments Totaling US$40 Million; Pharmaceutical R&D Chiefs Offer Support
- PRNewswire - Monday October 9, 2000
- BANGKOK, Thailand , Oct. 9 /PRNewswire/ -- The Global Alliance for TB Drug Development, a public-private partnership for the discovery of new drugs to treat one of the world s deadliest infectious diseases, was inaugurated today at the International Conference on Health Research for Development by its stakeholders from
- AIDS Healthcare Foundation's Medi-Cal Campaign Nets Governor's Backing: California to Seek State Insurance for Poor With HIV
- PRNewswire - Monday October 9, 2000
- LOS ANGELES, Oct. 9 /PRNewswire/ -- Californians facing HIV will soon receive state-funded health insurance coverage thanks to a four-year AIDS Healthcare Foundation (AHF) effort now endorsed by Governor Gray Davis. Medi-Cal will soon abandon AIDS-related disability as a requirement for HIV treatment for the poor, sai
- Nation's Largest AIDS Conference Ends with Challenges For the New Millennium; USCA 2000 Explored Meeting the Needs of the Diverse Communities Infected And Affected by HIV/AIDS Across the Country and Across the Globe
- PRNewswire - October 4, 2000
- ATLANTA, Oct. 4 /PRNewswire/ -- Remembering the past and building the future was the theme of the US Conference on AIDS 2000 (USCA) held October 1- 4, 2000 in Atlanta, Georgia. With over 3,300 participants, it was the largest AIDS conference held in the US and by all accounts one of the most diverse. Sponsored by Washi
- National Council of Negro Women Releases Report on AIDS: NCNW highlights HIV/AIDS Impact on African Women
- PRNewswire - October 3, 2000
- WASHINGTON, Oct. 3 /PRNewswire/ -- The National Council of Negro Women (NCNW) today released A Devastating Tragedy: AIDS in Africa, a detailed report on the challenges that HIV/AIDS is posing for nations in sub-Saharan Africa. NCNW was spurred to action by the horrifying statistics that one out of every five people in
- MAC Cosmetic's Kids Helping Kids Cards Raise Money for Children Living With HIV and AIDS Around the World: 1.2 Million Children Currently Living With HIV/AIDS and 3.2 Million Have Died From The Disease
- PRNewswire - October 2, 2000
- NEW YORK, Oct. 2 /PRNewswire/ -- Joy shines bright as MAC Cosmetics continues its fight against HIV and AIDS through the company s Kids Helping Kids Cards program. The cards, painted by children living with HIV/AIDS, raise money for other children living with HIV/AIDS. Colorful, all season cards illuminate lives and se
- Trinity Medical Group USA Announces Publication of Clinical Trial Results for Its HIV Treatment Using HIV-1 Immunogen (Remune)
- PRNewswire - September 29, 2000
- SAN RAFAEL, Calif., Sept. 29 /PRNewswire/ -- Trinity Medical Group USA, Inc. announces the publication of results of a human clinical study of its Immune Based Therapy for the treatment of HIV (HIV-1 immunogen or Remune(TM)) following scientific peer-review. The study, entitled A Double-Blind, Adjuvant-Controlled Trial
- HIV Resistance to Antiretrovirals Challenged by Ampligen
- PRNewswire - September 28, 2000
- NEW YORK, Sept. 28 /PRNewswire/ -- At today s New York-based meeting of the International AIDS Society entitled Current Challenges in HIV Disease held at the Hilton Hotel, over 2000 clinicians, research scientists and other health care practitioners were greeted by a major announcement of a new clinical initiative to a
- Hollis-Eden Pharmaceuticals Receives Clearance From the South African Government to Initiate Additional HIV Clinical Trials
- PRNewswire - September 27, 2000
- SAN DIEGO, Sept. 27 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced clearance from the South African Medicines Control Council (MCC) for the Company to initiate additional clinical studies in HIV infected patients with HE2000, its lead investigational drug candidate. These new studies i
- Anthem Blue Cross and Blue Shield Wins National Award for Improving Women's and Children's Health: HERA Award Given for HIV Testing Program for Pregnant Women
- PRNewswire - September 26, 2000
- CINCINNATI, Sept. 26 /PRNewswire/ -- For the second straight year, Anthem Blue Cross and Blue Shield (Anthem) has received the Gold HERA Award for helping improve women s and children s health. Presented annually, this national award is co-sponsored by the National Managed Health Care Congress (NMHCC) and Wyeth-Ayerst
- First MVA Vaccine for AIDS Cleared for Human Testing; IAVI-Sponsored Vaccine is Designed Specifically for Africa
- PRNewswire - September 21, 2000
- BONN, Germany , Sept. 21 /PRNewswire/ -- An AIDS vaccine candidate designed specifically for Africa and manufactured in Germany has been approved for human testing. Wayne Koff Ph.D., Vice President for Research and Development of the International AIDS Vaccine Initiative (IAVI), announced today that the Medicines Contr
- First MVA Vaccine for AIDS Cleared for Human Testing; IAVI-Sponsored Vaccine is Designed Specifically for Africa
- PRNewswire - September 21, 2000
- BONN, Germany , Sept. 21 /PRNewswire/ -- An AIDS vaccine candidate designed specifically for Africa and manufactured in Germany has been approved for human testing. Wayne Koff Ph.D., Vice President for Research and Development of the International AIDS Vaccine Initiative (IAVI), announced today that the Medicines Contr
- New Herpes Vaccine Similar to One for AIDS: VaxGen Scientist Used Same Principle to Develop Both Vaccines
- PRNewswire - September 20, 2000
- BRISBANE, Calif., Sept. 20 /PRNewswire/ -- The same principle used to develop the first successful herpes vaccine, whose efficacy data were unveiled this week, was also used to develop a preventive HIV/AIDS vaccine currently in the final stage of clinical testing. Both vaccines were produced by cloning key proteins on
- Nature Publication Describes New Insight Into Immune Control of AIDS Virus; Could Enable Development of Preventive HIV Vaccine
- PRNewswire - September 20, 2000
- SAN DIEGO, Sept. 20 /PRNewswire/ -- Researchers at The University of Wisconsin, in collaboration with Epimmune Inc. (Nasdaq: EPMN), reported new insight into how the immune system controls the AIDS virus in a non-human primate model. These findings may facilitate the development of a preventive vaccine against the huma
- Study confirms VirtualPhenotype(TM) Can Predict Response to HIV Therapy from Genetic Resistance Information - Test May Fulfill Need for Standardized Interpretation
- PRNewswire - September 20, 2000
- TORONTO, Sept. 20 /PRNewswire/ -- Results presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) indicate that the VirtualPhenotype(TM), Virco s new automated HIV drug resistance test, can predict response to therapy from genetic information with comparable results to a pan
- No Difference in Adherence Indicated in Survey of Patients On Anti-HIV Combination Therapies Containing Twice or Once Daily Agents
- PRNewswire - September 19, 2000
- TORONTO, Sept. 19 /PRNewswire/ -- The following press release was issued today by Meditech Media: Roche Pharmaceuticals today reported results from a survey that showed no difference in adherence to therapy between twice-daily (BID) and once-daily (QD) dosing regimens, among people living with HIV. The survey was desig
- Study Evaluates Dosage Adjustments of Glaxo Wellcome's Agenerase Including Addition of Ritonavir: Preliminary Data Evaluating Dosage Modifications in Patients Treated With Agenerase and Efavirenz or Nevirapine Presented at ICAAC Meeting: Effect of Ritonavir on Plasma Levels of Amprenavir Also Studied
- PRNewswire - September 19, 2000
- TORONTO, Sept. 19 /PRNewswire/ -- A study that evaluated dosage adjustments of the protease inhibitor (PI) Agenerase (R) ( amprenavir ) capsules in HIV patients treated with efavirenz or nevirapine
- LabCorp(R) Presents HIV Study Suggesting Frequently Monitored Patients Show Better Suppression of HIV Viral Load: LabCorp(R) Releases the Latest Trends on HIV Viral Load to be Presented at The Interscience Conference on Antimicrobial Agents and Chemotherapy
- PRNewswire - September 19, 2000
- BURLINGTON, N.C., Sept. 19 /PRNewswire/ -- Laboratory Corporation of America(R) Holdings (NYSE: LH) (LabCorp(R)), the nation s leading provider of HIV tests, today presented its latest findings on HIV viral load trends in the United States at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
- AnorMED presents data on new oral HIV entry inhibitor: New HIV drug candidate shown effective in preclinical studies
- PRNewswire - September 19, 2000
- VANCOUVER, Sept. 19 /PRNewswire/ - Data on a new orally-administered drug candidate with the potential to block HIV from entering and infecting healthy T-cells was presented today by AnorMED Inc. (TSE: AOM ) at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Toronto. Michael J. Abra
- NARVAL Study Using Visible Genetics' TRUGENE(TM) HIV-1 Genotyping Kit Shows Positive Outcome for HIV-Infected Patients
- PRNewswire - September 19, 2000
- TORONTO, Sept. 19 /PRNewswire/ -- Updated NARVAL data presented yesterday during the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) showed a better long term virologic benefit to HIV-infected patients who received HIV drug resistance genotype testing over those patients who received Stand
- Pharmacokinetics of Sustiva(TM) Unaffected When Used in Conjunction With Selective Serotonin Reuptake Inhibitors in HIV Positive Patients
- PRNewswire - September 19, 2000
- TORONTO, Sept. 19 /PRNewswire/ -- Pharmacokinetic data presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy suggest that, when selective serotonin reuptake inhibitors (SSRIs) are used at the same time that patients with HIV infection are receiving DuPont Pharmaceuticals
- Better World Advertising: KGO-TV Rejects HIV Prevention Commercial
- PRNewswire - September 19, 2000
- SAN FRANCISCO, Sept. 19 /PRNewswire/ -- The first ever HIV prevention television commercial aimed at HIV positive gay/bi men and transgenders has been banned from the airwaves by KGO-TV. KGO Channel 7 is the San Francisco ABC/Disney affiliate. The spot, HIV STOPS WITH ME, is part of an innovative new campaign featuring
- The Immune Response Corporation Announces the Addition of REMUNE(TM), An Investigational Therapeutic Vaccine for the Treatment of Primary HIV Infection, to the 'QUEST' Study Glaxo Wellcome's QUEST Study to Test Anti-HIV Strategy of Combining Very Early HAART Intervention and HIV Vaccination to Maintain Viral Suppression After Treatment Is Stopped
- PRNewswire - September 19, 2000
- CARLSBAD, Calif., Sept. 19 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that REMUNE(TM) (HIV-1 Immunogen), an investigational therapeutic vaccine for the treatment of HIV infection, will be tested as part of a clinical trial entitled QUEST. Glaxo Wellcome (NYSE: GLX) is the main sp
- Virco US Laboratories Approved to Perform Routine HIV Resistance Testing; Baltimore Facility Gains CAP and NY State Accreditation
- PRNewswire - September 19, 2000
- BALTIMORE, Sept. 19 /PRNewswire/ -- Virco Lab Inc., the U.S. subsidiary of Virco, has successfully passed College of American Pathologists (CAP) and New York State inspections. Accreditation by these bodies means Virco can now provide its advanced HIV drug resistance monitoring services to U.S. physicians directly from
- Tibotec Discloses Data on a Novel NNRTI; Highly Active Against Drug Resistant HIV Strains
- PRNewswire - September 19, 200
- MECHELEN, Belgium , Sept. 19 /PRNewswire/ -- Tibotec, an emerging international pharmaceutical company focused on the development of new drugs for HIV/AIDS today presented very positive results on one of its lead anti-HIV drugs, R165335-TMC125, at the 40th Interscience Conference on Antimicrobial Agents and Chemotherap
- Havana Study Shows Benefits of Genotype Testing: - Study Utilized Visible Genetics' TRUGENE HIV-1 Genotyping Kit -
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- In a study of 274 antiretroviral-experienced HIV patients, researchers today reported that genoptypic testing is of significant benefit as compared to standard of care (SOC) treatment in a variety of drug-experienced populations. Results from the six-month, randomized, prospective, mul
- Crixivan(R) and ritonavir in Twice-Daily Combination Markedly Suppressed Viral Levels in Protease Inhibitor-Naive Patients, New Preliminary Clinical Study Results Showed
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- Preliminary study results showed Crixivan (R) ( indinavir sulfate) administered as an investigational twice-daily 800-mg dose with a low dose of ritonavir(A) (100 mg) suppressed levels of HIV to below the limits of detection in patien
- Virco Launches Online Physician Access to its HIV Drug Resistance Tests: Service Designed to Improve Quality of Care by Providing Instant Information on Test Status
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- Virco today announced the availability of online access to their HIV drug resistance tests via a new service named VircoTrack(TM), the world s first pharmacogenomic service on the Internet. With VircoTrack(TM), healthcare professionals have secure access to status reports on tests that
- Recent Study Describes a Possible New Treatment Strategy for HIV/AIDS Patients - Trial Examines Substituting an NNRTI for a PI in Combination Therapy -
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- New findings show that 86% of patients (63 out of 73) with undetectable levels of HIV who switched treatment from a protease inhibitor (PI)-based regimen to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen maintained suppression of HIV (Amplicor(R) assay; 200 copi
- Phase III Data Show More Patients Taking Abbott Laboratories' Kaletra(TM) (lopinavir/ritonavir) Regimen Achieved Undetectable Levels of HIV Than Patients Taking Viracept(R) (nelfinavir) Regimen
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- Data at 40 weeks from an ongoing Phase III study (M98-863) presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy showed a significantly higher percentage of patients new to HIV therapy taking Abbott Laboratories protease inhibitor (PI), KaletraTM
- The Philadelphia AIDS Consortium, AmeriCorps and Philadelphia Health Commissioner Announce New Health Initiative for HIV/AIDS Community State Senator Shirley Kitchen, Member Public Health and Welfare Committee, Joins TPAC for Announcement
- PRNewswire - September 18, 2000
- PHILADELPHIA, Sept. 18 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC), a local non-profit organization and major funder of support services to individuals with HIV/AIDS, today announced a new health care initiative for the HIV/AIDS community. TPAC was joined today by Philadelphia Health Commissioner Walter Tso
- Triangle Pharmaceuticals and Abbott Laboratories Report Drug Candidate DAPD Decreases Viral Load in Patients Infected With Resistant Virus When Added to Failing Drug Regimens - DAPD May Provide New Salvage Therapy Option -
- PRNewswire - September 18, 2000
- DURHAM, N.C., Sept. 18 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) and Abbott Laboratories (NYSE: ABT) today announced the preliminary results of a Phase I/II trial in which DAPD produced impressive decreases in the viral loads of a cohort of five HIV-infected patients who were failing their antiviral
- Agouron Announces a Capravirine Clinical Trial For People Who Have Failed Previous Anti-HIV Therapy
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today announced that it has initiated an additional trial of the investigational drug capravirine, for the treatment of HIV infection, as part of combination therapy in people who have failed previous therapy. Capravirine will be investigated in a double-
- Progenics Reports New Triple Drug Cocktail Potently Blocks HIV
- PRNewswire - September 18, 2000
- TORONTO, Sept. 18 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that a triple drug cocktail of PRO 542, PRO 140 and T-20 acts synergistically to potently block HIV infection in vitro. Each of these drugs inhibits a different step in the sequence of events leading to the entry of HIV into targ
- Glaxo Wellcome Announces: Estimated Costs of Treating Abnormal Fat Distribution and Metabolic Abnormalities In HIV-Infected Individuals
- PRNewswire - September 17, 2000
- TORONTO, Sept. 17 /PRNewswire/ -- The first-year costs to manage a single symptom of an increasingly common complication associated with HIV/AIDS therapy could range from $410 to $7,369 per patient, according to a pharmacoeconomic modeling study presented here today at the 40th annual meeting of the Interscience Confer
- Long-Term Data Indicates Sustiva(TM) Highly Effective & Well Tolerated In Combination With D4t And 3tc In High Viral Load Treatment-Naive Patients Data Highlight the Use of Sustiva in a Variety of HIV-Infected Patients
- PRNewswire - September 17, 2000
- TORONTO, Sept. 17 /PRNewswire/ -- Data presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy indicate that the combination of DuPont Pharmaceuticals (NYSE: DD) Sustiva (TM) ( efavirenz ),
- Data Indicate Longer Virologic Response in Patients Who Switch From a Protease Inhibitor to a Regimen Containing Sustiva(TM)
- PRNewswire - September 17, 2000
- TORONTO, Sept. 17 /PRNewswire/ -- Data presented today indicate that DuPont Pharmaceuticals (NYSE: DD) anti-HIV drug Sustiva (TM) ( efavirenz ), when substituted for a protease inhibitor, successfully maintains viral load suppression (less than 50 copies/mL) in patien
- Long-Term Study Results Show That SUSTIVA(TM) (efavirenz), Is Effective When Used with ZERIT(R) (stavudine) and EPIVIR(R) (lamivudine) In Treating Naive Patients with High and Low Viral Loads
- PRNewswire - September 17, 2000
- TORONTO, Sept. 17 /PRNewswire/ -- According to 84 week results from a clinical trial presented today at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), SUSTIVA, when used with ZERIT and EPIVIR, was a well-tolerated three-drug regimen effective in reducing viral load in treatment-naive
- Basketball Great Magic Johnson Opens AIDS Clinic: Oakland Facility Offers Care to Uninsured
- PRNewswire - September 15, 2000
- OAKLAND, Calif., Sept. 15 /PRNewswire/ -- Wishing healthy, productive and long lives to Oakland residents with AIDS, basketball great Magic Johnson today dedicated a new HIV clinic in Oakland, California, named in his honor and operated by the AIDS Healthcare Foundation (AHF). (Photo: http://www.newscom.com/cgi-bin/prn
- California Gov. Davis Signs Landmark Bill Mandating HMOs Provide AIDS Specialists: Gallegos' AB 2168 Requires 'Standing Referral' - HMO's Will Be Forced to Contract With Specialists If None in Plan
- PRnewswire - September 15, 2000
- LOS ANGELES, Sept. 15 /PRNewswire/ -- Governor Gray Davis this week signed landmark legislation ordering California HMOs to provide AIDS specialists for patients infected with HIV. The new law by Assemblyman Martin Gallegos gives patients a legal right to obtain care from physicians who have demonstrated expertise in
- Abbott Laboratories Gains FDA Approval For HIV Treatment Kaletra(TM) (Lopinavir/Ritonavir), Formerly Known as ABT-378/r Phase II/III Studies Across a Spectrum of HIV Patients Support Accelerated Approval
- PRNewswire - September 15, 2000
- ABBOTT PARK, Ill., Sept. 15 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) announced today it received accelerated U.S. Food and Drug Administration ( FDA ) approval to market its antiretroviral, Kaletra (TM) ( lopinavir /
- Landmark Study on Lipodystrophy Demonstrates Evolving Perceptions By Physicians Who Treat People Living With HIV
- PRNewswire - September 14, 2000
- TORONTO, Sept. 14 /PRNewswire/ -- Physicians who treat people living with HIV are less conclusive about the causes of lipodystrophy, a condition that affects some people living with HIV. Seventy-one percent of physicians believe that the causes of lipodystrophy are multifactorial, compared to 53% who recalled believing
- HIV STOPS WITH ME Commercial First to Address Prevention for Positives
- PRnewswire - September 13, 2000
- SAN FRANCISCO, Sept. 13 /PRNewswire/ -- The first ever HIV prevention television commercial aimed at HIV positive gay/bi men and transgenders will be premiered September 14th, 2000 in San Francisco. HIV prevention messages up until now have not targeted those men who already know they are HIV positive. As part of an in
- Glaxo Wellcome Launches Living4Life to Increase Early HIV Diagnosis, Treatment
- PRNewswire - September 13, 2000
- WASHINGTON, Sept. 13 /PRNewswire/ -- To help stem the HIV/AIDS epidemic in communities where the virus is spreading fastest, pharmaceutical leader Glaxo Wellcome today announced the nationalization of a peer-to-peer approach modeled after the focused intervention concept utilized at the OASIS clinic in the Watts neighb
- MEE Awarded Multimillion-Dollar CDC Contract to Promote HIV Testing Nationally
- PRNewswire - September 12, 2000
- PHILADELPHIA, Sept. 12 /PRNewswire/ -- MEE (Motivational Educational Entertainment) Productions Inc., an international communications and marketing firm specializing in urban issues, has been selected by the U.S. Centers for Disease Control and Prevention (CDC) to develop HIV testing campaigns and communications materi
- Once-A-Day HAART Regimen Containing Coviracil(R)(Emtricitabine) Demonstrates Potent and Sustained Antiviral Activity Over 48-Weeks in HIV-Infected Patients -- Data Presented at the 38th Annual Meeting of the Infectious Disease Society of America --
- PRNewswire - September 11, 2000
- DURHAM, N.C., Sept. 11 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that researchers from the Agence Nationale de Recherche sur le SIDA (ANRS) in France presented the one-year results of a pilot study of a once-a-day HAART (highly active antiretroviral therapy) regimen, combining Covira
- Scientists Call for HIV Vaccine Moratorium: Durban Declaration 'A Farce'
- PRNewswire - September 9, 2000
- ARLINGTON, Va., Sept. 9 /PRNewswire/ -- The following is being issued by the Chronic Illness Research Foundation: Scientists today called for a moratorium on all HIV vaccine research and clinical trials until the mechanism of AIDS is further elucidated. The official call for a moratorium will appear in the October 2000
- AIDS Treatment News Special Survival Issue Reviews Benefits of Therapy, Answers Fringe Groups: Free Copies Available to Public
- PRNewswire - September 8, 2000
- SAN FRANCISCO, Sept. 8 /PRNewswire/ -- AIDS Treatment News, a twice-monthly newsletter published continuously for 14 years, devotes its current issue #350 to the effect of modern treatment on survival of persons with HIV infection or AIDS. Designed for physicians to give to patients when necessary, but available free t
- RESCRIPTOR(R)-Containing Combination Therapy May Be Effective For People Failing Previous Anti-HIV Therapies
- PRNewswire - September 8, 2000
- NEW ORLEANS, Sept. 8 /PRNewswire/ -- Malte Schutz, MD (Illinois Masonic Medical Center, Chicago, IL) and William Owen, MD (California Pacific Medical Center, San Francisco, CA) reported a study today which evaluates the durability of anti-HIV therapy including RESCRIPTOR(R) ( delavirdine
- Epimmune Awarded NIH Grant for Development of HIV Vaccine Therapy: Preclinical/Clinical Program to Advance Epitope-Based Vaccines Into Human Trials
- PRNewswire - August 15, 2000
- SAN DIEGO, Aug. 15 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN) announced today that it has been awarded a $3.8 million grant from the Integrated Preclinical/Clinical Program (IPCP) of the National Institutes of Health (NIH), Division of AIDS, for the development of a new vaccine approach to treat people infected with
- Boston Biomedica Announces Signing of Cooperative Research and Development Agreement (CRADA) With NIH For Evaluating Use of Pressure Cycling Technology (PCT) in Diagnostics:Joint research programs to focus on extraction of nucleic acids from specimens and inactivation of viral pathogens prior to testing
- PRnewswire - August 11, 2000
- WEST BRIDGEWATER, Mass., Aug. 11 /PRNewswire/ -- Boston Biomedica, Inc. (Nasdaq: BBII) announced today the signing of a Cooperative Research and Development Agreement with the National Institutes of Health Clinical Center (NIHCC) to develop applications of BBI s proprietary Pressure Cycling Technology (PCT) for clinica
- AIDS Treatment Activists Urge Federal Clinical Studies of IL-2, Reticulose, Ampligen at Republican and Democratic National Conventions
- PRnewswire - August 11, 2000
- NEW YORK, Aug. 11 /PRNewswire/ -- AIDS treatment activists from ACT UP Brooklyn, Women s AIDS Research and the International Immune Based Therapy Working Group have joined together to lobby delegates to make the availability of developing HIV therapies a campaign issue. The necessity to provide the FDA
- Triangle Pharmaceuticals Announces the Continued Development of Coactinon (R) (Emivirine)
- PRNewswire - August 10, 2000
- DURHAM, N.C., Aug. 10 /PRNewswire/ -- Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today its continued development of Coactinon in support of an NDA filing. Coactinon is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection. This action follows notification from the
- Progenics and Pharmacopeia Announce New Collaborative Agreements: Discovery Programs Focus on Small-Molecule Therapeutics for HIV and a Second Antiviral Target
- PRNewswire - August 10, 2000
- TARRYTOWN, N.Y., and PRINCETON, N.J., Aug. 10 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Pharmacopeia, Inc. (Nasdaq: PCOP) have announced the initiation of two new collaborative programs to discover orally active antiviral agents. The target for the first program is the HIV envelope glycoprotein
- Yolanda Adams, Brian McKnight, Kirk Whalum, Nancy Wilson and Trin-I-Tee 5:7 Encourage African Americans to be Tested for HIV on "Get Tested Days": Glaxo Wellcome and the City of Houston Organize All-Star Concert And Free HIV Testing Events at Seven Local Sites
- PRNewswire - August 9, 2000
- HOUSTON, Aug. 9 /PRNewswire/ -- Thousands of Houston residents are expected to be tested for HIV and attend an all-star R&B and gospel concert on Get Tested Days, Aug. 10 and Aug. 11. The local campaign was organized by a coalition including individuals from the City of Houston s Health Dept., the mayor s office, t
- FRC Calls for Presidential Candidates to State Their Policy On African Aids Crisis
- PRNewswire - August 8, 2000
- WASHINGTON, Aug. 8 /PRNewswire/ -- Family Research Council s Robert Maginnis, vice president for national security and foreign affairs, returned Monday from investigating the AIDS problem in South Africa . AIDS is causing the desolation of human life in South Africa, yet the U.S. is perpetuating the problem by funding
- VircoLab Awarded Major HIV Resistance Testing Contract by Centers for Disease Control
- PRNewswire - August 8, 2000
- BALTIMORE, Aug. 8 /PRNewswire/ -- The Centers for Disease Control (CDC) has awarded a major contract to Virco to conduct the testing for its pivotal survey of transmission of drug-resistant strains of HIV in the U.S. The total contract is worth over $400,000. This is the first major contract with the U.S. government ag
- Healthcare Workers Face National Crisis - Conference Focuses on Safety Needs of America's Workers -
- PRNewswire - August 4, 2000
- WASHINGTON, Aug. 4 /PRNewswire/ -- For the first time, Diane Mawyer, RN, is telling the traumatic story of her exposure to hepatitis C (HCV) through a needlestick injury on the job, and her subsequent fight for life through three organ transplants, at a meeting here of the Frontline Healthcare Workers Safety Foundatio
- Abbott Laboratories Raises Awareness of Expansion of Kaletra(TM) (Lopinavir/Ritonavir) Early Access Program : Abbott Lifts Criteria for Patients to Enroll in Program --
- PRNewswire - August 4, 2000
- ABBOTT PARK, Ill., Aug. 4 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) Kaletra , formerly ABT-378/r, Early Access Program now has availability for more patients. Kaletra is Abbott s investigational HIV protease inhibitor currently in Phase III clinical trials. In January, Abbott expanded its Early Access program cr
- Leader in Needlestick Safety Sponsors Chase House Benefit at 6th World Congress for Nurse Anesthetists
- PRnewswire - August 3, 2000
- CHICAGO, Aug. 3 /PRNewswire/ -- The Vascular Access Business unit of Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, today announced it will sponsor the American Association of Nurse Anesthetists (AANA) Party with a Purpose charity event, Sunday, August 6, from 8 p.m. to midnight, at the Hyatt Regency, Chi
- Vitex and Red Cross Extend Transfusion Plasma Contract: Distribution Rights Expanded to Next Generation Universal PLAS+(R)SD: Company Previews Second Quarter Results
- PRNewswire - August 1, 2000
- WATERTOWN, Mass., Aug. 1 /PRNewswire/ -- V.I. Technologies, Inc. (VITEX) (Nasdaq: VITX) announced today that it has signed an agreement with the American National Red Cross (ANRC) for a six year extension of its exclusive distribution agreement for virally-inactivated transfusion plasma products. Notably, the extension
- Virginia's Pat Funderburk Ware to Speak on HIV/AIDS Awareness at Republican National Convention
- PRNewswire - August 1, 2000
- PHILADELPHIA, Aug. 1 /PRNewswire/ -- Pat Funderburk Ware, president and CEO of the Preserving Family Well-Being Foundation, will speak at the Republican National Convention this evening. The evening s program will be dedicated to Governor George W. Bush s theme of Strength and Security With a Purpose: Safe in Our Homes
- People With HIV Wanted for Interleukin-2 Study at Abbott Northwestern Hospital
- PRNewswire - July 31, 2000
- MINNEAPOLIS, July 31 /PRNewswire/ -- Abbott Northwestern Hospital is searching for people with HIV who are willing to try an experimental treatment using Interleukin-2, a substance that has been licensed to fight certain cancers. Interleukin-2 is a naturally occurring protein that stimulates the body s immune response.
- Ampligen Viewed as the Next Hope for HIV Antiretroviral Resistance
- PRNewswire - July 27, 2000
- NEW YORK, July 27 /PRNewswire/ -- The close of the 13th World AIDS Conference has led to an increased emphasis in the pursuit of effective methods of treating drug resistant HIV. The 13th World AIDS Conference has left us with definitive evidence that the need exists for effective therapies to treat resistant HIV. The
- Denial of HIV/AIDS: an Issue in U.S., as Well as Africa: Stigma Prevents Many African Americans From Seeking Diagnostic Testing or Treatment of HIV/AIDS: Nationally Televised Forum Focuses on HIV/AIDS Denial And Other Domestic and International AIDS Issues
- PRNewswire - July 27, 2000
- CHICAGO, July 27 /PRNewswire/ -- Last evening, Reverend Jesse L. Jackson, Sr. hosted a Town Hall Forum on the HIV/AIDS epidemic in the African American community as part of the Rainbow/PUSH Coalition s Annual Convention. The event, Ending the Silence: Ending the Epidemic , was broadcast live nationally on the Black Ent
- AIDS Treatment Activists Call for Fast Track Development of Reticulose
- PRNewswire - July 26, 2000
- NEW YORK, July 26 /PRNewswire/ -- With the close of the 13th International AIDS Conference, a coalition of leading AIDS Treatment activists are demanding better access to Reticulose, a lipoprotein-nucleic acid complex manufactured by Advanced Viral Research that has shown promise in the treatment of many of the symptom
- Progenics Announces Publication of Encouraging Clinical Results With HIV Drug
- PRNewswire - July 20, 2000
- TARRYTOWN, N.Y., July 20 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the publication of a scientific article describing the initial clinical trial of PRO 542, the Company s most clinically advanced HIV inhibitor. In the study, a single dose of PRO 542 demonstrated measurable antiviral
- Montana Group Awarded Grant for AIDS Care in Africa: Maternal Life International (MLI) of Butte Receives $273,000 Grant From Bristol-Myers Squibb Company for AIDS Prevention and Care in Swaziland, Africa; Care Based on MLI's Unique Accessible Parish-Nurse Model
- PRNewswire - July 20, 2000
- BUTTE, Mont., July 20 /PRNewswire/ -- Maternal Life International (MLI), a Butte-based non-profit world health care and disease prevention organization that focuses on women and children, has been awarded a $273,000 grant by Bristol-Myers Squibb (NYSE: BMY), a global health and personal care company, to implement a par
- Major Development in ML's DNA Custom Manufacturing Business; Novel HIV Vaccine to Use ML's Patented DNA Manufacturing Technology
- PRNewswire - July 20, 2000
- LONDON, July 20 /PRNewswire/ -- The DNA manufacturing division of Cobra Therapeutics, a subsidiary of the UK emerging pharmaceutical company ML Laboratories, has just received regulatory approval to produce DNA for the clinical trials of a novel DNA vaccine against HIV subtype A, which is the most common strain in many
- As Number of Women With HIV/AIDS Grows, Public Health Officials Look to Female Condom Programs: National Conference of State Legislatures Told of Cost-Effectiveness And Availability of The Female Condom by President of The Female Health Company
- PRnewswire - July 19, 2000
- CHICAGO, July 19 /PRNewswire/ -- With U. S. Centers for Disease Control statistics showing increasing sexually transmitted disease (STD) including HIV/AIDS infection among American women, public health officials and policymakers are examining ways to help women protect themselves and their families from the dreaded dis
- AIDS Healthcare Foundation Announces Grand Opening of New Oakland, CA Earvin 'Magic' Johnson, Jr. Clinic: State-of-the-Art AIDS Healthcare Facility to Offer Underserved Populations In Alameda County Improved Access to Quality Care, Services
- PRNewswire - July 19, 2000 TX
- What: Ribbon Cutting & Reception, Grand Opening of new community AIDS facility, Earvin Magic Johnson, Jr. Clinic at AHF s Healthcare Center/Oakland When: THURSDAY, JULY 20th 11a.m. - 1p.m. Program begins: 11:30am, Ribbon Cutting: 12 noon Where: Earvin Magic Johnson, Jr. Clinic at AHF s Healthcare Center/Oakland (ad
- European CPMP gives positive opinion on Trizivir, a new triple combination therapy for HIV
- PRNewswire - July 18, 2000
- LAVAL, Quebec, July 18 /CNW - PRN/ -BioChem Pharma Inc. (NASDAQ: BCHE; TSE: BCH) announced today that the European Union s Committee for Proprietary Medicinal Products (CPMP) has recommended the approval of Trizivir , Glaxo Wellcome s new triple combination tablet developed for the treatment of HIV-infected adults, in
- Potent Results Seen With Combination of Sustiva(TM) and Investigational Protease Inhibitor ABT-378/r for HIV Treatment: Additional Data Support Role of Sustiva in Treatment Of PI-experienced Patients
- PRNewswire - July 17, 2000
- WILMINGTON, Del., July 17 /PRNewswire/ -- Data recently presented suggest that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and the experimental protease inhibitor ABT-378/
- Study Suggests Switching from Protease Inhibitors to Sustiva(TM) Maintains Viral Load Suppression in HIV-Positive Patients: Additional Data Demonstrate Sustiva Improves Triglyceride Levels & Viral Load Reduction
- PRNewswire - July 17, 2000
- WILMINGTON, Del., July 17 /PRNewswire/ -- Data presented at a major medical meeting last week demonstrate that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), a non-nucleoside reverse transcriptase inhibitor (NNRTI), may provide an effective and safe
- New Data Suggest Switching to Sustiva(TM) from Protease Inhibitors Successfully Maintains Antiretroviral Control
- PRNewswire - July 17, 2000
- WILMINGTON, Del., July 17 /PRNewswire/ -- Data recently presented indicate that DuPont Pharmaceuticals anti-HIV drug Sustiva (TM) ( efavirenz ), when substituted for a protease inhibitor, successfully maintained viral load suppression (less than 50 copies/mL) in patie
- POZ Exclusive: Nushawn Williams, The 'AIDS Monster' Who Infected 13 Women, Gives First In-Depth Interview in August Cover Story: The August POZ Also Features First-Ever List of 'HIV Criminals' - More Than 100 Profiles of Men and Women Convicted of Attempting To Infect Others Through Sex, Biting and More - and Asks, 'Does the Punishment Fit the Crime?'
- PRNewswire - July 14, 2000
- NEW YORK, July 14 /PRNewswire/ -- In a POZ magazine cover story, Nushawn Williams, the young African American the media called The AIDS Monster in 1997, goes on record for the first time saying that he didn t know he had HIV when he had sex with 28 women in New York s Chattaqua County. Williams is currently serving fou
- Clinical Data on REMUNE(TM) (Investigational HIV-1 Immunogen) Selected as a Late Breaker Presentation at the XIII International AIDS Conference in Durban, South Africa: Preliminary Results Suggest the Investigational Use of HIV Immune-Based Therapy Alone or in Combination With Antiviral Drugs to Treat HIV-Infected Individuals
- PRNewswire - July 14, 2000
- CARLSBAD, Calif., July 14 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that Trinity Medical Group, the Company s licensee for development of REMUNE in Southeast Asia, has informed the Company that follow-up data from the Phase II clinical trial conducted in Thailand were pre
- International AIDS Conference Webcast Attracts Thousands In First Week webcast.aids2000.com
- PRNewswire - July 14, 2000
- DURBAN, South Africa , July 14 /PRNewswire/ -- More than 20,000 people from around the world logged on to webcast.aids2000.com during the first days of the XIII International AIDS Conference held this week in Durban, South Africa. The conference, which is the largest international HIV meeting, takes place once every tw
- Virco Identifies Emerging HIV Drug Resistance in Africa
- PRewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- Two studies using Virco s HIV drug resistance monitoring systems as part of the UNAIDS Drug Access Initiative have revealed the development of high levels of resistance in African countries pioneering the use of antiretrovirals on this continent. The study, conducted in
- Survey of Patient Adherence Indicates No Difference Between Anti-HIV Combination Therapies Given Once or Twice Daily
- PRNewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported no difference in adherence to therapy among a survey of people living with HIV that was designed to compare adherence rates between either the HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) twice daily (BID) or non-nuc
- Latebreaker Data on Atlantic Study Shows a VIRAMUNE-based Treatment Combination is Comparable to a Protease Inhibitor-based Regimen
- PRNewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- Findings from the Atlantic study indicate that VIRAMUNE(R) ( nevirapine ) + two nucleoside analogues has shown similar efficacy to indinavir * + two nucleoside analogues.
- First Once-Daily VIRACEPT(R) Data Presented
- PRNewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported a study in healthy volunteers indicating that an investigational once-daily dosing (QD) of the HIV protease inhibitor VIRACEPT(R) (nelfinavir mesylate) in combination with small doses of
- VaxGen Emerges as Leader in AIDS Vaccine Development Nine Scientific Presentations Made at Durban AIDS Conference
- PRNewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- VaxGen Inc. s (Nasdaq: VXGN) leadership in developing worldwide HIV/AIDS vaccines was highlighted this week at the XIII International AIDS Conference as researchers presented scientific updates on the company s late-stage clinical trials. (Photo:http://www.
- Virco Identifies Emerging HIV Drug Resistance in Africa
- PRNewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- Two studies using Virco s HIV drug resistance monitoring systems as part of the UNAIDS Drug Access Initiative have revealed the development of high levels of resistance in African countries pioneering the use of antiretrovirals on this continent. The study, conducted in
- Killer T Cells Against the AIDS Virus Appear to be Activated By Combination Treatment With REMUNE(TM) (Investigational HIV-1 Immunogen) and Antiviral Drugs
- PRNewswire - July 13, 2000
- CARLSBAD, Calif., July 13 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that preliminary interim clinical results from an ongoing Phase II trial in Spain indicate that functionally active cytotoxic T lymphocytes (CTL) or killer T cells appear to be stimulated in HIV-positive individuals
- VaxGen Emerges as Leader in AIDS Vaccine Development: Nine Scientific Presentations Made at Durban AIDS Conference
- PRNewswire - July 13, 2000
- DURBAN, South Africa , July 13 /PRNewswire/ -- VaxGen Inc. s (Nasdaq: VXGN) leadership in developing worldwide HIV/AIDS vaccines was highlighted this week at the XIII International AIDS Conference as researchers presented scientific updates on the company s late-stage clinical trials. In nine separate presentations
- HIV/AIDS International Prayer Ceremony to Be Held in Napa Valley
- PRNewswire - July 12, 2000
- NAPA VALLEY, Calif., July 12 /PRNewswire/ -- On August 15, 2000, the Glass Chapel at the di Rosa Art Preserve in Napa Valley will host a dusk-to-dawn puja (sanskrit for prayer ceremony ) in remembrance of those who have died of AIDS and honoring those living with HIV/AIDS. The once in a lifetime event, according to the
- Aquila's QS-21 Adjuvant Maintains Immune Response of HIV Vaccine at Low Antigen Doses: Study, presented at International AIDS conference, highlights potential for lowering gp120 vaccine manufacturing costs, developing multivalent vaccines
- PRNewswire - July 12, 2000
- FRAMINGHAM, Mass., July 12 /PRNewswire/ -- Researchers from the University of Rochester reported today on a human study demonstrating that Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA) proprietary vaccine adjuvant, QS-21, and substantially reduced amounts of the HIV gp120 antigen, produced high levels of antibodies in
- Virco's Antivirogram(TM) Proves Effective for Less-Prevalent HIV Strains: Antivirogram(TM) is the Only Test Proven to Work in All Group M Subtypes and Group O
- PRNewswire - July 12, 2000
- DURBAN, South Africa , July 12 /PRNewswire/ -- Data presented today at the 13th International Conference on AIDS from Virco s Antivirogram(TM) resistance test indicate that a second generation of HIV drugs may be highly active against the strains of HIV found in developing countries. The phenotypic test used in the stu
- Secure the Future Funds Vital Study Aimed at Reducing Mother to Child Transmission of HIV/AIDS
- PRNewswire - July 12, 2000
- - Groundbreaking project aimed at reducing the rate of mother-to-child transmission of HIV at the Perinatal HIV Research Unit at the University of the Witwatersrand. - Bristol-Myers Squibb Company s Secure the Future program to provide grant of US$700 thousand (R4,2 million).Epitope, Inc. contributing $50,000 (R300 tho
- Data Show VIRAMUNE(R) (nevirapine) Combination Suppresses HIV in Patients with Advanced HIV/AIDS
- PRNewswire - July 12, 2000
- DURBAN, South Africa , July 12 /PRNewswire/ -- Study results presented today at the 13th International AIDS Conference in Durban, South Africa show a VIRAMUNE(R) ( nevirapine , NVP) treatment combination suppressed HIV in the blood for up to one year in patients with advanced HIV disease and high baseline
- Researchers Unveil Data on VIRAMUNE(R) (nevirapine) for Prevention of Mother-to-Child Transmission of HIV in Developing Countries - More than 1,300 South African Women Participate in Landmark SAINT Trial -
- PRNewswire - July 12, 2000
- DURBAN, South Africa , July 12 /PRNewswire/ -- A study evaluating VIRAMUNE(R) (nevirapine) versus ZDV + 3TC * for the prevention of mother-to- child transmission (MTCT) of HIV was presented at the 13th International AIDS Conference. While VIRAMUNE is not currently indicated for the prevention of MTCT, re
- Childreach, US Member of PLAN International, Receives $1 Million Grant From Bill & Melinda Gates Foundation to Develop Initiative for African Children Affected by HIV/AIDS
- PRNewswire - July 12, 2000
- DURBAN, S.A., July 12 /PRNewswire/ -- A $1 million grant from the Bill & Melinda Gates Foundation has been awarded to Childreach, the US member of PLAN International - one of the world s largest child-focused development organizations - to develop an initiative to help the millions of African children affected by H
- Elizabeth Glaser Pediatric AIDS Foundation Awarded $15 Million by the Bill & Melinda Gates Foundation to Prevent Mother-to-Child Transmission of HIV
- PRNewswire - July 12, 2000
- DURBAN, South Africa , July 12 /PRNewswire/ -- The Elizabeth Glaser Pediatric AIDS Foundation announced today that the Bill & Melinda Gates Foundation has awarded a $15 million grant directed to its newest global initiative, the Call to Action Project, to reduce mother-to-infant HIV transmission globally. This gift
- Decision Resources, Inc., Announces HIV 2000 - Major and Emerging Markets New Study Evaluates Market Drivers for Current and Emerging Anti-HIV Therapies And Forecasts Potential Sales in Global Markets Through 2009
- PRNewswire - July 11, 2000
- WALTHAM, Mass., July 11 /PRNewswire/ -- In the early 1980s, when HIV was first identified as the causative agent of AIDS, no one could have predicted the impact this disease would have. In the past two decades, more than 50 million people have become infected and roughly 17 million have died. In some countries, as many
- 72-week Phase II Data on ABT-378/r Presented at World AIDS Conference Duration of Response Analyses from Ongoing Phase II Studies in Treatment-Naive And PI-Experienced Patients
- PRNewswire - July 11, 2000
- ABBOTT PARK, Ill., July 11 /PRNewswire/ -- Data from two ongoing Phase II studies of Abbott Laboratories investigational protease inhibitor (PI), ABT-378/r ( lopinavir / ritonavir ), at 72 weeks continue to show suppression of HIV in both patients new to therapy and patients who have failed othe
- Hollis-Eden Presents Promising HIV Study Results at World AIDS Conference In South Africa; Investigational Drug HE2000 Targets Immune System
- PRNewswire - July 11, 2000
- SAN DIEGO, July 11 /PRNewswire/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) today announced the presentation of clinical data from HIV-infected patients being treated with the Company s investigational drug candidate HE2000 in a Phase I/II clinical trial in South Africa . The data were presented in a poster ses
- For People Living With HIV, VIRACEPT(R) Combination Therapy Was Shown to Suppress Virus for Three Years
- PRNewswire - July 11, 2000
- DURBAN, South Africa , July 11 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported that, in a long-term study, a majority of people living with HIV who received VIRACEPT(R) (nelfinavir mesylate) combination therapy for three years in this clinical trial were shown to experience suppre
- RESCRIPTOR(R) Has Shown to Enhance HIV Protease Inhibitor Therapy
- PRNewswire - July 11, 2000
- DURBAN, South Africa , July 11 /PRNewswire/ -- Agouron Pharmaceuticals, Inc. today reported results from studies evaluating safety and efficacy of RESCRIPTOR(R) ( delavirdine mesylate) Tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of
- First AIDS Vaccine Designed for Africa Is Cleared for Testing in Humans IAVI's Scientific Blueprint 2000 Seeks Head-to-Head Trials And Compressed Timelines; With 'Goal in Sight,' IAVI Urges US$1.1 Billion in New Funding for Focused R&D Effort
- PRNewswire - July 11, 2000
- DURBAN, South Africa , July 11 /PRNewswire/ -- The first AIDS vaccine candidate designed specifically for Africa will enter human trials this summer. The International AIDS Vaccine Initiative (IAVI) announced today that the Medicines Control Agency (MCA) of the United Kingdom has approved Phase I testing o
- Glaxo Wellcome Study of Agenerase Combined with Low-dose Ritonavir In PI- experienced Patients Combination Raised Plasma Levels of Amprenavir
- PRNewswire - July 11, 2000
- Preliminary Study Suggests: Plasma Levels of Amprenavir Are Raised By Low- Dose Ritonavir DURBAN, South Africa , July 11 /PRNewswire/ -- Preliminary results of a study of the protease inhibitor (PI)
- The Female Condom Helps Women Take Control of HIV/AIDS Prevention
- PRNewswire - July 10, 2000
- DURBAN, South Africa , July 10 /PRNewswire/ -- In response to more than 40 percent of new HIV infections globally occurring in women, The Female Health Company (OTC Bulletin Board: FHCO), provider of The Female Condom(TM), is increasing efforts to help women in developing countries understand their role in prevention a
- First ABT-378/r Pediatric Data Presented at World Aids Conference
- PRNewswire - July 10, 2000
- ABBOTT PARK, Ill., July 10 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT) presented the first data in infants and children with the company s investigational protease inhibitor (PI), ABT-378/r ( lopinavir / ritonavir ) today at the 13th World AIDS Conference
- The Bill & Melinda Gates Foundation, Merck & Co., Inc. And the Republic of Botswana Launch New HIV Initiative
- PRNewswire - July 10, 2000
- SEATTLE, and WHITEHOUSE STATION, N.J., July 10 /PRNewswire/ -- The Bill & Melinda Gates Foundation, Merck & Co. , Inc. (NYSE: MRK)(1) and the Republic of Botswana today announced the establishment of the Botswana Comprehensive HIV/AIDS Partnership , a new initiative to improve the overall state of HIV/AIDS care
- IAVI Issues Blueprint to Assure Global Access to AIDS Vaccines Action Needed Now to Provide Simultaneous Access for Rich and Poor; Gates, Mandela and Leading Vaccine Manufacturers Embrace Goal
- PRNewswire - July 9, 2000
- DURBAN, South Africa , July 9 /PRNewswire/ -- The development pipeline for AIDS vaccines was virtually empty two years ago. Today, there are promising products in development but still no plan to get any useful vaccine to the most affected communities in the world. The International AIDS Vaccine Initiative (IAVI) today
- Phase II Results Show Significant Increase in CD4 Counts Without Producing A Sustained Increase in Viral Load Levels in HIV-Infected Patients Receiving rhIL-2: Data Published in the Journal of the American Medical Association (JAMA) And Highlighted at American Medical Association (AMA) Media Briefing For International AIDS Conference
- PRNewswire - July 8, 2000
- EMERYVILLE, Calif., July 8 /PRNewswire/ -- Chiron (Nasdaq: CHIR) announced today that results from a Phase II study of Chiron s recombinant human interleukin-2 (rhIL-2, or aldesleukin) in patients with HIV infection show that patients receiving rhIL-2 in conjunction with standard antiretroviral therapy achieved signifi
- Phase II Results Show Significant Increase in CD4 Counts Without Producing A Sustained Increase in Viral Load Levels in HIV-Infected Patients Receiving rhIL-2: Data Published in the Journal of the American Medical Association (JAMA) And Highlighted at American Medical Association (AMA) Media Briefing For International AIDS Conference
- PRNewswire - July 8, 2000
- EMERYVILLE, Calif., July 8 /PRNewswire/ -- Chiron (Nasdaq: CHIR) announced today that results from a Phase II study of Chiron s recombinant human interleukin-2 (rhIL-2, or aldesleukin) in patients with HIV infection show that patients receiving rhIL-2 in conjunction with standard antiretroviral therapy achieved signifi
- Female Health Company and UNAIDS Launch Guide, Other Initiatives at July 11 Satellite Symposium
- PRNewswire - July 7, 2000
- DURBAN, SOUTH AFRICA, July 7 /PRNewswire/ -- The Female Health Company (Amex: FHCO) has teamed up with The Joint United Nations Programme on HIV/AIDS ( UNAIDS ) and the World Health Organization (WHO) to create a new educational guide about The Female Condom. The partners will launch the Guide at a satellite sympos
- Regions Hospital: Dr. Keith Henry Signs Durban Declaration; Historic Document Sets Sights on HIV in Africa
- PRNewswire - July 7, 2000
- ST. PAUL, Minn., July 7 /PRNewswire/ -- Dr. Keith Henry, medical director of the HIV/AIDS Program at Regions Hospital, is one of 5,000 AIDS specialists including Nobel prizewinners, directors of leading research institutions, scientific academies and medical societies worldwide, to sign the Durban Declaration, a statem
- Surgeon General to Host Press Conference in South Africa To Bring HIV/AIDS Impact Home to U.S.: Press Conference With Leading Federal Health Officials to Be Held on July 9, 2000
- PRNewswire - July 6, 2000
- DURBAN, South Africa , July 6 /PRNewswire/ -- Surgeon General David Satcher will host a July 9 press conference with leading Federal officials on the devastating impact of HIV/AIDS on the United States , especially among communities of color. The press conference, which will be a precursor to week long events during th
- Secure the Future HIV/AIDS Grants in Southern Africa Now Exceed US$31.5 Million (R189 Million): 17 new grants totaling US$7.5 million (R45 million) announced
- PRNewswire - July 6, 2000
- JOHANNESBURG, South Africa , July 6 /PRNewswire/ -- Five countries in the sub-Saharan region are to receive seventeen Secure the Future grants more than US$7.5 million (R45 million), to support medical research and community outreach and education projects aimed at combating HIV/AIDS. This brings the total Secure the F
- Antiretroviral Drugs Require 95 Percent Adherence to Work, Find Researchers at University of Pittsburgh Medical Center: Study Also Finds Doctors Are Often Wrong About Patients' Adherence
- PRNewswire - July 6, 2000
- PITTSBURGH, July 6 /PRNewswire/ -- A computerized medication monitoring system has shown that HIV patients must be at least 95 percent adherent to antiretroviral therapy for the drugs to work, report investigators from the University of Pittsburgh Medical Center (UPMC). In a startling twist, the study also reveals that
- Antiretroviral Drugs Require 95 Percent Adherence to Work, Find Researchers at University of Pittsburgh Medical Center: Study Also Finds Doctors Are Often Wrong About Patients' Adherence
- PRNewswire - July 6, 2000
- PITTSBURGH, July 6 /PRNewswire/ -- A computerized medication monitoring system has shown that HIV patients must be at least 95 percent adherent to antiretroviral therapy for the drugs to work, report investigators from the University of Pittsburgh Medical Center (UPMC). In a startling twist, the study also reveals that
- FDA Approves AmBisome(R) for the Treatment of Cryptococcal Meningitis in AIDS Patients: Fujisawa and Gilead Drug Becomes First Lipid Agent Approved for Indication
- PRNewswire - July 5, 2000
- DEERFIELD, Ill., and FOSTER CITY, Calif., July 5 /PRNewswire/ -- Fujisawa Healthcare, Inc. and Gilead Sciences , Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration ( FDA ) approved the antifungal drug AmBisome(R) ( (amphotericin B) liposome for injection) for the treatment of cryptococcal meningit
- AIDS Treatment Activists to Rally for Vaccine Development At 13th World AIDS Conference
- PRNewswire - July 5, 2000
- NEW YORK, July 5 /PRNewswire/ -- AIDS Treatment activists from around the world will be rallying for acceleration of HIV vaccine research at the 13th World AIDS Conference in Durban, South Africa to begin July 19, 2000. The successful development of an HIV vaccine is the only answer for the future of 70 million people
- Genome Scientist Posts Position Statement on the Role of HIV in AIDS
- PRNewswire - July 3, 2000
- BERKELEY, Calif., July 3 /PRNewswire/ -- Genome scientist Dr. Howard Urnovitz offered his insight into the role of HIV in AIDS for the upcoming Durban 13th International AIDS Conference. One topic the conference will be addressing is the decade old debate of what role the virus HIV plays in AIDS. Dr. Urnovitz s researc
- Virax and IDT In Australian Consortium Which Wins $27 Million Contract Award From NIH to Develop and Test Vaccines to Prevent HIV/AIDS
- PRNewswire - June 27, 2000
- MELBOURNE, Australia , June 27 /PRNewswire/ -- Virax Holdings Limited (ASX: VHL) and Institute of Drug Technology Australia Limited (ASX: IDT) today announced that, the Australian consortium, of which they are a member, is to receive $27 million (US$16) from the US National Institutes of Health (NIH) to fast track the
- NIAID Public-Private Partnerships Seek to Develop HIV/AIDS Vaccine
- PRNewswire - June 27, 2000
- BETHESDA, Md., June 27 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID) announced today four novel public-private partnerships to accelerate development of promising HIV/AIDS vaccines for use around the world. The new partnerships, called HIV Vaccine Design and Development Teams (HVDDT)
- Chiron Awarded NIH Contract to Develop HIV Vaccine Chiron Will Receive $24 Million in Funding From NIH's National Institute of Allergy and Infectious Diseases (NIAID) to Advance Its HIV Vaccine Program Into Human Trials
- PRNewswire - June 27, 2000
- EMERYVILLE, Calif., June 27 /PRNewswire/ -- Chiron Corporation (Nasdaq: CHIR) announced today that the company has been awarded a five year contract from the National Institutes of Health (NIH) to advance its HIV vaccine program into human clinical trials. The total value of the contract to Chiron will be approximately
- Hemispherx Biopharma: New Presidential Order Will Accelerate Patient Accrual and Treatment in Both CFS and AIDS Clinical Programs
- PRNewswire - June 27, 2000
- PHILADELPHIA, June 27 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said that the recent Executive Order by President Clinton to increase benefits of Medicare Beneficiaries in Clinical Trials should significantly accelerate enrollment in, and expansion of, its major U.S.-based clinical trials in both AI
- Surgeon General Urges More Americans to Get Tested for HIV
- PRnewswire - June 26, 2000
- WASHINGTON, June 26 /PRNewswire/ -- Surgeon General David Satcher today said more Americans should take control of their health by getting tested for the HIV virus. An estimated 250,000 people in the United States are unaware that they are infected with HIV, the virus that causes AIDS, Satcher said. Testing is a crit
- XIII International AIDS Conference to be Broadcast on World Wide Web webcast.aids2000.com
- PRNewswire - June 26, 2000
- DURBAN, South Africa , June 26 /PRNewswire/ -- People with HIV disease and healthcare professionals from around the world will be able to view sessions from the XIII International AIDS Conference on the World Wide Web, according to organizers of this global meeting. The Webcast (webcast.aids2000.com) will feature scien
- AIDS Activists Call for Immediate Approval of Epitope's Oral Fluid Rapid HIV Test
- PRNewswire - June 23, 2000
- NEW YORK, June 23 /PRNewswire/ -- Immediately following a legislative forum attended by Congressmen Ed Towns, Major Owens and Nydia Valasquez with people living with AIDS in Brooklyn on Monday, AIDS activists began to rally for the immediate FDA approval of the first reliable rapid oral fluid test OraQuick, for HIV man
- AIDS Advocates Encourage New Clinical Research on Ampligen
- PRNewswire - June 22, 2000
- NEW YORK, June 22 /PRNewswire/ -- In a surprising announcement by William Carter, MD, CEO of Hemispherix Biopharma, it was made known today that Hemispherix Biopharma will be retaining Anderson Clinical Research to conduct clinical trials on Ampligen for the treatment of drug resistant HIV. For the past year, at the re
- Biosyn, Inc. Announces Phase I Clinical Results for SAVVY(R) Microbicide
- PRNewswire - June 22, 2000
- PHILADELPHIA, June 22 /PRNewswire/ -- Biosyn, Inc. announced today that a Phase I clinical trial for SAVVY vaginal microbicide, currently under development, has concluded with results indicating that SAVVY may be a safe and effective method of contraception. This study, conducted at the University of Pennsylvania Medic
- AmeriCorps Serving HIV/AIDS Communities
- PRNewswire - June 21, 2000
- PHILADELPHIA, June 21 /PRNewswire/ -- The Philadelphia AIDS Consortium (TPAC) today announced that it has been selected as a National AmeriCorps site. Luciano Orsini, President of the Consortium s Board of Directors said, We are thrilled to have been chosen in this highly competitive, national process to serve as a dir
- Rev. Jesse L. Jackson, Sr. and 10,000 AIDS Organizations Urge People at Risk for HIV to 'Take the Test and Take Control'; CDC Research Show National HIV Testing Day Campaign Increases Number of HIV Tests
- PRNewswire - June 21, 2000
- WASHINGTON, June 21 /PRNewswire/ -- To help identify nearly 250,000 people in the United States who do not know they are infected with HIV, the virus that causes AIDS, the National Association of People with AIDS (NAPWA) announced today the sixth annual National HIV Testing Day, June 27. NAPWA is urging Americans at ri
- Interim Results in a Patient Subset Indicate That Treatment With REMUNE(TM) and Antiviral Drugs May Stimulate 'Killer' T Cell Activity; Clinical Trial Data from Phase 2 Spanish Trial Reported at the Fifth European Conference on Experimental AIDS Research (ECEAR) 2000
- PRNewswire - June 21, 2000
- CARLSBAD, Calif., June 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today preliminary interim clinical results which indicate REMUNE(TM) (HIV-1 Immunogen) may stimulate cytotoxic T lymphocytes (CTL) or killer T cell activity specifically against HIV, the AIDS virus, in people infected wit
- Hemispherx Biopharma: FDA Authorizes Advanced Clinical Study In Multi-Drug Resistant HIV Disease
- PRNewswire - June 26, 2000
- PHILADELPHIA, June 26 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said it has just received FDA authorization to conduct a major Phase 2/3 clinical study in HIV disease resistant to